METHOD FOR TREATING HUMAN PERSPIRATION USING A CATION AND AN ANION IN THE PRESENCE OF A MODULATOR

Abstract

The present invention relates to a cosmetic process for treating human perspiration and optionally body odors resulting from perspiration, which includes the use of at least one cation Xn+ of valence n, at least one anion Ym- of valence m and at least one modulating agent.

Description

(i) either the mixing just before use of at least one composition A and at least one composition B; said compositions A and B being packaged separately followed by the application of the resulting mixture to the surface of the skin; (ii) either the simultaneous or sequential application to the skin surface of at least one composition A and at least one composition B packaged separately; (iii) either the application to the skin surface of a composition comprising in the same carrier at least one composition A and at least one composition B; said composition A comprising in a cosmetically acceptable at least one cation Xn+ of valence n; said composition B comprising in a cosmetically acceptable at least one anion Ym' of valence m; the mixture of said composition A with said composition B comprising in addition at least one modulating agent. The armpits, as well as certain other parts of the body, are often the site of various discomforts that may stem directly or indirectly from perspiration. These discomforts often lead to unpleasant and embarrassing sensations, primarily due to the presence of sweat. This sweat can, in some cases, make the skin feel damp and wet clothes, particularly in the armpits or on the back, leaving visible marks. Furthermore, the presence of sweat can cause body odor, which is usually unpleasant. Finally, as sweat evaporates, it can also leave salts and / or proteins on the skin's surface, which can cause whitish stains on clothing. Such discomforts should be taken into account even in cases of moderate perspiration. In the cosmetics field, it is well known to use topical antiperspirant products containing substances that limit or even eliminate perspiration in order to address the problems mentioned above. These products are generally available in roll-on, stick, aerosol, or spray form. Antiperspirants are generally composed of aluminum and / or zirconium chlorohydrates. These substances reduce the flow of sweat by forming a plug at the sweat duct. However, using these substances at high concentrations to achieve good efficacy leads to formulation difficulties. Furthermore, it has been observed that the antiperspirant efficacy of these substances is limited when used alone. This implies that these substances need to be applied repeatedly to the skin to achieve a satisfactory antiperspirant effect. Finally, these antiperspirant substances can also leave traces when applied, which results in staining clothes. To address all the aforementioned drawbacks, it has been proposed to search for other effective active substances that are well tolerated by the skin and easily formulate. It has already been proposed in application US20070196303 to use calcium and / or strontium type cations in the presence of a buffer consisting of an amino acid and a betaine to enhance the activity of aluminum chlorohydrates. Application WO0010512 also proposed using calcium-type cations in the presence of an acidic solution based on an amino acid and / or a hydroxy acid to enhance the activity of aluminum and / or zirconium salts. The presence of aluminum and / or zirconium salts remains mandatory in these antiperspirant formulations. As an alternative to aluminum and / or zirconium chlorohydrates, patent WO2013 / 013902 already proposed a multi-component antiperspirant agent comprising a first component consisting of a cosmetic composition A and a second component consisting of a cosmetic composition B different from cosmetic composition A, intended to be mixed before application to the skin or to be applied to the skin simultaneously, separately, or at different times. Cosmetic composition A comprises a multivalent cation halide, and composition B comprises a nitrogen-free salt of an anion. However, the method of application is rather inconvenient for the consumer. Therefore, there is a genuine need for a skin-applied agent for treating human perspiration that does not present all the drawbacks described above; that is, one that provides a satisfactory antiperspirant effect, particularly in terms of efficacy and resistance to perspiration, and that is well-tolerated by the skin. Furthermore, there is a need for such an agent for treating human perspiration that can be used alone or in combination with an additional antiperspirant. Finally, such an agent must be able to be formulated in a way that is stable during storage. The Plaintiff discovered, to her surprise, that this objective could be achieved by using a cosmetic process for treating human perspiration and possibly body odors resulting from the transpiration, which includes the use of at least one cation Xn+ of valence n, at least one anion Ym' of valence m and at least one modulating agent. The present invention therefore relates to a cosmetic process for treating human perspiration and possibly body odors resulting from perspiration, which includes the use of at least one cation Xn+ of valence n, at least one anion Ym' of valence m and at least one modulating agent. When the cation Xn+ of valence n, the anion Ym' of valence m and the modulating agent are formulated in anhydrous medium, they can be present within the same composition (i.e. a single composition). Alternatively, they can be formulated in two different compositions, one comprising the n-valent cation Xn+ (composition A), and the other comprising the m-valent anion Ym' (composition B). The modulating agent, meanwhile, can be present in composition A and / or in composition B. According to one variant, the modulating agent is not introduced into either composition A or composition B, but is generated during the mixing of compositions A and B. When the cation Xn+ of valence n, the anion Ym' of valence m and the modulating agent are formulated in an aqueous medium (i.e. comprising an aqueous phase, for example an aqueous solution or an oil-in-water or water-in-oil emulsion), the cation is necessarily formulated in a composition separate from the anion. Thus, according to this embodiment, preferably: - the cation Xn+ with valence n is present in a composition A; - the anion Ym' with valence m is present in a composition B, compositions A and B being different, and composition A and / or B comprising at least one aqueous phase; and - the modulating agent, for its part, is present in composition A and / or in composition B. According to a variant, the modulating agent is not introduced into composition A or into composition B, but is generated during the mixing between compositions A and B. Preferably, the present invention relates to a cosmetic process for treating human perspiration and optionally body odors resulting from perspiration, which includes (i) either the mixing just before use of at least one composition A and at least one composition B, said compositions A and B being packaged separately, followed by the application of the resulting mixture to the surface of the skin; (ii) either the simultaneous or sequential application to the skin surface of at least one composition A and at least one composition B packaged separately; (iii) either the application to the skin surface of a composition comprising in the same carrier at least one composition A and at least one composition B; said composition A comprising in a cosmetically acceptable at least one cation Xn+ of valence n; said composition B comprising in a cosmetically acceptable at least one anion Ym' of valence m; the mixture of said composition A with said composition B comprising in addition at least one modulating agent. According to a first embodiment, the modulating agent may be present in composition A and / or in composition B. According to a second embodiment, it may also not be present in composition A or in composition B, but be generated in situ following the mixing of said compositions A and B. Such a process according to the invention is effective in the treatment of human perspiration. Furthermore, compositions A and B are stable during storage. The present invention also relates to a ready-to-use cosmetic composition, in particular for the treatment of human perspiration and optionally body odor resulting from perspiration, comprising, in a cosmetically acceptable medium, at least one n-valent cation Xn+, at least one m-valent anion Ym', and at least one modulating agent. This composition is referred to in this application as a "ready-to-use composition." By "ready to use," we mean that the composition is applied to the skin surface very quickly after its preparation, for example, from a few seconds to a few minutes after preparation. Typically, the time between mixing the n-valent cation(s) Xn+, m-valent anion(s) Ym', and modulator(s) and application to the skin is 0 to 30 minutes, preferably 0 to 10 minutes, preferably 0 to 1 minute, and preferably 0 to 30 seconds. The term "antiperspirant agent" means any substance or composition that has the effect of reducing the flow of sweat and / or reducing the sensation of dampness associated with human sweat and / or masking human sweat. By "cosmetically acceptable medium", we mean a medium compatible with the skin and / or its appendages or mucous membranes which has a pleasant color, smell and feel and which does not generate discomforts (such as tightness) likely to deter the consumer from using this composition. The aforementioned cosmetically acceptable medium is also one that leaves no traces when applied, and therefore does not stain clothes. The cosmetically acceptable medium may be anhydrous or comprise an aqueous phase. Preferably, it comprises an aqueous phase. In particular, the cosmetically acceptable medium of the ready-to-use composition preferably comprises an aqueous phase. By "cation Xn+", we mean any ionic compound, preferably inorganic, comprising one or more positive charges; the valence n indicating the number of positive charges. By "anion Ym'", we mean any ionic compound, preferably inorganic, comprising one or more negative charges; the valence m indicating the number of negative charges. By "sequential", we mean a successive administration. By "same support", it is meant that compositions A and B according to the invention are present in the same packaging, in particular a two-compartment packaging which allows the simultaneous application of compositions A and B. CATION X n+ The Xn+ cations according to the invention are preferably chosen from among the multivalent inorganic cations whose valence n is by definition at least 2, preferably 2, 3 or 4. Multivalent inorganic Xn+ cations are preferably chosen from: - alkaline earth cations such as Magnesium (Mg2+) or Calcium (Ca2+); and - transition metal cations such as Titanium (Ti4+), Manganese (Mn2+, Mn3+, Mn4+), Iron (Fe2+, Fe3+), Copper (Cu2+), Zinc (Zn2+) or Zirconium Multivalent inorganic Xn+ cations are preferably chosen from among the alkaline earth cations. The preferred alkaline earth cations will be chosen from Magnesium (Mg 2+) and Calcium (Ca2+). The preferred transition metal cations will be chosen from Zinc, Manganese, Iron and Titanium. The cations according to the invention are introduced into the single anhydrous composition, into composition A, or into the ready-to-use composition, in the form of water-soluble salts. For the purposes of the present invention, "water-soluble salt" means any salt which, after being completely dissolved under stirring at 0.5% in a water solution at a temperature of 25°C, results in a solution containing less than 0.05% by weight of insoluble salt. Preferably, water-soluble salts of the Xn+ cation are chosen from among halides, sulfates, and carboxylates. Indeed, among the cation salts Xn+ that can be used according to the invention, halides can be mentioned. The halides used will be fluorides (Fluoride), chlorides (Chlorine), bromides (Bromine), and iodides (Iodine), and more particularly chlorides. Among the water-soluble salts of Xn+ cations usable according to the invention, we can also mention carboxylic acid salts or carboxylates such as acetates, propionates, and pyrrolidone carboxylates (or pidolates); polyhydroxylated carboxylic acid salts such as gluconates, heptagluconates, and ketoglutonates; mono- or polycarboxylic hydroxy acid salts such as citrates and lactates; and amino acid salts such as aspartates, glutamates, and ascorbic acid salts. Acetate salts, lactate salts, and aspartate salts will be used more particularly. We can also mention sulfates such as magnesium sulfate, ferric sulfates, zinc sulfates. Examples of Xn+ cation salts according to the invention include Magnesium chloride, Calcium chloride, Calcium pidolate, Calcium aspartate, Calcium gluconate, Calcium glutamate, Calcium heptagluconate, Calcium propionate, Calcium 2-ketogluconate, Calcium lactate, Calcium ascorbate, Calcium citrate, Magnesium acetate, Magnesium pidolate, Magnesium gluconate, Magnesium glutamate, Magnesium heptagluconate, Magnesium 2-ketogluconate, Magnesium lactate, Magnesium ascorbate, Magnesium citrate, Magnesium aspartate, or Manganese gluconate. We can also mention sulfates such as Magnesium sulfate. Preferably, choose Calcium chloride, Magnesium chloride, Calcium acetate, Magnesium lactate, Calcium citrate and Magnesium citrate. Preferably, composition A, comprising at least one Xn+ cation according to the invention, includes an aqueous phase and has a pH between 2 and 6, preferably between 3 and 5. If necessary, the pH is adjusted with a cosmetically acceptable acid or base, organic or mineral. Such an acid and such a base are those conventionally used in cosmetics. Composition A includes at least one cation Xn+ of valence n, and does not contain any anion(s) Ym' of valence m as counter-ion(s). Preferably, composition A comprises at least one cation Xn+ of valence n in a content of between 0.5 and 30% by weight relative to the total weight of composition A, preferably between 1 and 25% by weight. Similarly, preferably the single anhydrous composition comprises at least one Xn+ cation of valence n in a content of between 0.5 and 30% by weight relative to the total weight of the composition, preferably between 1 and 25% by weight. According to a particular embodiment of the invention, composition A comprises a mixture of cations Xn+ of valence n, and does not contain any anion(s) Ym' of valence m. According to a preferred embodiment of the invention, composition A comprises a cation Xn+ of valence n, and does not contain anion(s) Ym' of valence m. According to another embodiment of the invention, the "ready-to-use composition" comprises a cation Xn+ of valence n, and one or more anion(s) Ym' of valence m, preferably an anion Ym' of valence m. ANION Ym' The anions Ym' according to the invention preferably have a valence m of at least 2, preferably 2, 3, or 4. They are preferably inorganic. They are preferably chosen from among carbonate (CO32-), hydrogen carbonate (HCO3-), phosphate (PO43-), polyphosphates such as diphosphate P2O74- (also called pyrophosphate), triphosphate PsO105-, phosphonate (PO3'), hydrogen phosphate (HPO42-), sulfate (SO42-), sulfonate (SO32'), hydrogen sulfate (HSO4), hydrogen sulfonate (HSO3), and silicate (SiO2). Hydrogen phosphate or hydrogen carbonate will be used more particularly. The anions Ym' according to the invention are introduced into the single anhydrous composition, into composition B, or into the ready-to-use composition, in the form of a water-soluble salt. For the purposes of the present invention, a "water-soluble salt" of an anion Ym' means any salt which, after being completely dissolved under stirring at 0.5% in a water solution at a temperature of 25°C, results in a solution containing less than 0.05% by weight of insoluble salt. The water-soluble salt of anion Ym can be chosen for example from: alkali metal salts such as potassium, sodium, and ammonium salts, such as alkanolamine salts (in particular mono-, di- or tri-alkanolamines), comprising one to three hydroxyalkyl radicals, identical or not, in Ci-C4. Among the alkanolamine compounds, we can mention monoethanolamine, diethanolamine, triethanolamine, monoisopropanolamine, diisopropanolamine, N-dimethylaminoethanolamine, 2-amino-2-methyl-1-propanol, triisopropanolamine, 2-amino-2-methyl-1,3-propanediol, 3-amino-1,2-propanediol, 3-dimethylamino-1,2-propanediol, tris-hydroxymethylaminomethane. Preferably, the Ym anion will be introduced in the form of an alkali metal salt, in particular a sodium or potassium salt. Among the preferred anion salts Ym', we can mention Na2CO3, K2CO3, NaHCO3, KHCO3, Na3PO3, Na2HPO4, NaH2PO4, Na2H2P2O7, Na4P2O7, K2HPO4, KH2PO4, K2H2P2O7, K4P2O7, Na2SO4, K2SO4. Preferably, we will use sodium hydrogen carbonate NaHCOs, or disodium hydrogen phosphate Na2HPO4. The molar ratio between the cation(s) Xn+ and the anion(s) Ym' varies preferably from 10:1 to 1:10 and more preferably from 4:1 to 1:4. The total concentration of cation(s) Xn+ and anion(s) Ym' varies preferably from 1 to 70% by weight and more preferably from 2 to 50% by weight relative to the total weight of compositions A and B (or in the ready-to-use composition or in the single anhydrous composition). Composition B includes at least one anion Ym' of valence m, and does not contain a cation Xn+ of valence n as a counter-ion. Preferably, composition B comprises at least one anion Ym' of valence m in a content of between 0.5 and 30% by weight relative to the total weight of composition B, preferably between 0.7 and 25% by weight. Similarly, preferably the single anhydrous composition comprises at least one anion Ym' of valence m in a content of between 0.5 and 30% by weight relative to the total weight of composition B, preferably between 0.7 and 25% by weight. According to a particular embodiment of the invention, composition B comprises a mixture of anions Ym' of valence m, and does not contain any cation(s) Xn+ of valence n. According to a preferred embodiment of the invention, composition B comprises an anion Ym' of valence m, and does not contain any cation(s) Xn+ of valence n. According to another embodiment of the invention, the "ready-to-use composition" comprises an anion Ym' of valence m, and one or more cation(s) Xn+ of valence n, preferably one cation(s) Xn+ of valence n. MODULATORS As previously stated, according to a first embodiment, the modulating agent(s) may be present in composition A and / or in composition B. Preferably, the modulating agent(s) is / are present in composition A. According to a second embodiment, it may also not be present in composition A or in composition B, but be generated in situ following the mixing of said compositions A and B. The modulating agent according to the invention can be chosen from among the complexing agents of the Xn+ cation(s) and the complexing agents of the Ym' anion(s). Preferably, the modulating agent according to the invention can be chosen from among the complexing agents of the Xn+ cation(s). The modulating agent according to the invention is different from the anion(s) Ym' and the cation(s) Xn+. In particular, it can be chosen from: - mono- or polycarboxylic acids (preferably di- or tricarboxylic), possibly hydroxylated (i.e., hydroxy acids), in free or salt form, such as propionic acid, citric acid, tartaric acid, lactic acid, malic acid, succinic acid, glutaric acid, itaconic acid, - Amino carboxylic acids in free or salted form such as aspartic acid, glutamic acid, serine, alanine, dehydroalanine and their oligomers, iminosuccinic acid and its derivatives, ethylenediaminetetraacetic acid, - Monosaccharides, oligosaccharides, polysaccharides, and their derivatives. Preferably, the monosaccharides are selected from glucose, galactose, mannose, xylose, lyxose, fucose, arabinose, rhamnose, ribose, deoxyribose, quinovose, fructose, sorbose, talose, threose, and erythrose. Preferably, the oligosaccharides comprise 2 to 6 monosaccharide units and are preferably selected from trehalose, lactose, maltose, and cellobiose. The derivatives are preferably selected from glucuronic acid and lactobionic acid. Finally, the polysaccharides are preferably chosen from alginates, chitosans and pectins, - ascorbic acid, - phytic acid, - polymers or copolymers of carboxylic acids in free or salted form such as the products sold under the name SOKOLAN CP42, CP44 by BASF, - polymers or copolymers of amino carboxylic acids in free or salted form, such as polyaspartic acid, for example the polymers mentioned in patents WO 9216462, WO 9403527 Srchem Incorp., and in particular a 30% sodium polyaspartate solution in water, such as the product sold under the trade name AQUADEW SPA-30 by Ajinomoto; polyglutamic acid, - polymers and copolymers of maleic or itaconic acid, - Carboxymethylinulin polymers and copolymers. Among the preferred modulators, when they must be added, are amino carboxylic acids in free or salified form, mono- or polycarboxylic acids possibly hydroxylated in free or salified form, ascorbic acid, polymers or copolymers of amino carboxylic acids in free or salified form such as polyaspartic acid, or polymers or copolymers of carboxylic acids in free or salified form. Citric acid, ascorbic acid, lactic acid, propionic acid, tartaric acid or polyaspartic acid will be used in particular, in free or salt form, or a polymer or copolymer of carboxylic acids possibly amines. According to a particular embodiment of the invention, composition A or composition B or the "ready-to-use composition" or the single anhydrous composition, comprise a mixture of modulating agents, preferably two modulating agents. Even more preferably, a mixture of free citric acid and citric acid in its salt form (or citrate), particularly a mixture of citric acid and sodium citrate, will be used as modulating agents. Even more preferably, the weight ratio (free citric acid) to (citric acid in its salt form) is between 1:4 and 1:2. The modulating agent(s) according to the invention may be present in composition A and / or B (or in the ready-to-use composition or in the single anhydrous composition) in a content of between 0.01 and 30% by weight relative to the total weight of composition A and / or B (or of the ready-to-use composition or of the single anhydrous composition), preferably between 0.03 and 10% by weight. Preferably, the weight ratio between the modulating agent(s) and the salt(s) of cation(s) Xn+ is between 0.01 and 1.5, preferably between 0.03 and 1. Preferably, the composition resulting from the mixture of compositions A and B (or the ready-to-use composition) has a pH between 5 and 8. APPLICATION METHOD To obtain an anti-perspirant effect on the skin, according to a first variant of the perspiration treatment process of the invention (embody (i)), composition A comprising at least one cation Xn+ and composition B comprising at least one anion Ym' shall be packaged separately and are mixed just before use (extemporaneous mixing) and then the mixture thus obtained is applied to the surface of the skin to be treated. According to a second variant of the antiperspirant process of the invention (embody (ii)), composition A comprising at least one cation Xn+ and composition B comprising at least one anion Ym' will be packaged separately and applied simultaneously or sequentially to the surface of the skin to be treated. According to this variant, when compositions A and B are applied sequentially, the time interval separating the application of composition A from the application of B can vary from 1 second to 24 hours, more preferably from 10 seconds to 24 hours and even more preferably from 1 minute to 1 hour. To obtain an anti-perspirant effect on the skin, according to a third variant of the perspiration treatment process of the invention (embody (iii)), a composition comprising in the same support composition A containing at least one cation Xn+, composition B containing at least one anion Ym' and at least one modulator is applied directly to the skin surface. Compositions A and B may each be independently anhydrous or include an aqueous phase. They will preferably be in the form of aqueous, alcoholic, or hydroalcoholic solutions. With regard in particular to the aforementioned embodiment (iii), compositions A and B may, for example, be packaged in a device comprising at least two compartments containing composition A and composition B respectively, such as a twin tube, a two-compartment pump bottle, an aerosol device comprising two compartments which may include one or more outlet orifices (single-nozzle or double-nozzle), a device with a perforated wall such as a grid comprising two compartments; a device comprising two compartments each equipped with a ball applicator (multi-ball roll-on); a double stick. Preferably, compositions A and B will be applied sequentially, and even more preferably, composition A, which includes at least one Xn+ cation, will be applied first. Preferably, compositions A and B will be applied sequentially, and even more preferably, composition A, comprising at least one Xn+ cation and at least one modulating agent, will be applied first. Galenic Forms Compositions A and / or B (or the ready-to-use composition or the single anhydrous composition) may independently be presented in all the pharmaceutical forms conventionally used for topical application, and in particular as aqueous gels, aqueous solutions, or hydroalcoholic solutions. Compositions A and / or B (or the ready-to-use composition) may also be anhydrous. They may also, by the addition of an oily or fatty phase, be presented as lotion-type dispersions, liquid or semi-liquid emulsions such as milk, obtained by dispersing an oily phase in an aqueous phase (O / W) or vice versa (W / O), or as suspensions or emulsions of soft, semi-solid, or solid consistency such as creams or gels, or as multiple emulsions (W / O / W or W / O / O), microemulsions, ionic and / or non-ionic vesicular dispersions, or wax / aqueous phase dispersions.These compositions A and / or B (or the ready-to-use composition or the single anhydrous composition) are prepared according to the usual methods. Compositions A and / or B may be packaged, in particular, in pressurized form in an aerosol device or pump bottle; packaged in a device with a perforated wall, such as a grid; packaged in a device with a roll-on applicator; packaged in stick form, or as a loose or compacted powder. They contain the ingredients generally used in this type of product and well known to those skilled in the art. According to another particular embodiment of the invention, compositions A and / or B or the ready-to-use composition or the single anhydrous composition, may be solid, in particular in the form of a rod or stick; in the form of a loose or compacted powder. By "solid composition" we mean that the measurement of the maximum force measured in texture analysis when a probe is inserted into the formula sample must be at least equal to 0.25 Newton, in particular at least equal to 0.30 Newton, especially at least equal to 0.35 Newton, assessed under precise measurement conditions as follows. To perform texture measurements, the formulas are hot-poured into pots 4 cm in diameter and 3 cm deep. Cooling is carried out at room temperature. The hardness of the prepared formulas is measured after 24 hours. The pots containing the samples are characterized by texture analysis using a texture analyzer such as the one marketed by Rhéo TA-XT2, according to the following protocol: a 5 mm diameter stainless steel ball probe is brought into contact with the sample at a speed of 1 mm / s. The measuring system detects the interface with the sample with a detection threshold of 0.005 newtons. The probe penetrates 0.3 mm into the sample at a speed of 0.1 mm / s. The measuring device records the evolution of the measured compressive force over time during the penetration phase.The hardness of the sample corresponds to the average of the maximum values ​​of the force detected during penetration, over at least 3 measurements. The invention also relates to a cosmetic treatment method for human perspiration, and possibly for body odors associated with human perspiration, consisting of applying to the skin surface, in particular to the surface of the armpits, an effective amount of composition A and an effective amount of composition B; or an effective amount of the ready-to-use composition; or an effective amount of a single anhydrous composition. The application time of composition A and / or B (or of the ready-to-use composition or of the single anhydrous composition) on the skin surface may vary from 0.5 to 10 seconds, preferably from 1 to 5 seconds. Compositions A and B (or the ready-to-use composition or the single anhydrous composition) can be applied repeatedly to the skin surface. They can be applied repeatedly, over one day or over several days. Another object of the present invention is an aerosol device consisting of a first container comprising a pressurized composition A, a second container comprising a pressurized composition B and a means for distributing the mixture of said composition. The dispensing mechanism, which forms part of the aerosol device, generally consists of a dispensing valve controlled by a dispensing head, itself comprising a nozzle through which the pressurized compositions A and B are vaporized into a mixture. The container holding the pressurized compositions A and B may be opaque or transparent. It may be made of glass, polymeric material, or metal, possibly coated with a protective varnish. Another object of the present invention is an aerosol device consisting of a container comprising a pressurized anhydrous composition comprising, in a cosmetically acceptable medium, at least one cation Xn+ of valence n, at least one anion Ym' of valence m and at least one modulating agent; and by a means for dispensing the mixture of said composition. The dispensing mechanism, which forms part of the aerosol device, generally consists of a dispensing valve controlled by a dispensing head, itself comprising a nozzle through which the pressurized anhydrous composition is vaporized. The container holding the pressurized anhydrous composition may be opaque or transparent. It may be made of glass, polymeric material, or metal, possibly coated with a protective varnish. Compositions A and / or B (or the ready-to-use composition or the single anhydrous composition) may also include at least one additional deodorant active ingredient and / or at least one additional antiperspirant active ingredient. For the purposes of this invention, "deodorant active" means any active ingredient which, by itself, has the effect of masking, absorbing, improving and / or reducing the unpleasant odor resulting from the decomposition of human sweat. Examples of these additional deodorant actives include bacteriostatic agents or bactericidal agents that act on axillary odor germs, such as 2,4,4'-trichloro-2'-hydroxydiphenyl ether (©Triclosan), 2,4-dichloro-2'-hydroxydiphenyl ether, 3',4',5'- trichlorosalicylan ilide, 1-(3',4'-dichlorophenyl)-3-(4'-chlorophenyl)urea (©Triclocarban) or 3,7,11-trimethyldodeca-2,5,1O-trienol (©Farnesol); quaternary ammonium salts such as cetyltrimethylammonium salts, cetylpyridinium salts; polyols such as those of the glycerin type, 1,3-propanediol (ZEMEA PROPANEDIOL® marketed by Dupont Tate and Lyle Bioproducts), 1,2-decanediol (Symclariol® from the company Symrise); Glycerin derivatives such as Caprylic / Capric Glycerides (CAPMUL MCM® from Abitec), Glycerol Caprylate or Caprate (DERMOSOFT GMCY® and DERMOSOFT GMC® respectively from STRAETMANS), Polyglyceryl-2 Caprate (DERMOSOFT DGMC® from STRAETMANS), biguanide derivatives such as polyhexamethylene biguanide salts; chlorhexidine and its salts; 4-Phenyl-4,4-dimethyl-2-butanol (SYMDEO MPP® from Symrise); cyclodextrins; or alum. The additional deodorant actives may preferably be present in the compositions according to the invention in weight concentrations ranging from 0.01 to 10% by weight relative to the total weight of the composition. By "anti-perspirant active ingredient" we mean any substance which, on its own, has the effect of reducing the flow of perspiration, reducing the sensation on the skin of moisture related to human sweat, and masking human sweat. As an illustration of these additional antiperspirant actives, one may cite in particular the antiperspirant salts or complexes of aluminium and / or zirconium, preferably chosen from aluminium halohydrates; aluminium and zirconium halohydrates, complexes of zirconium hydroxychloride and aluminium hydroxychloride with or without an amino acid such as those described in US patent 3792068. Among the aluminium salts, we can mention in particular aluminium chlorohydrate in activated or inactivated form, aluminium chlorohydrex, aluminium chlorohydrex polyethylene glycol complex, aluminium chlorohydrex propylene glycol complex, aluminium dichlorohydrate, aluminium dichlorohydrex polyethylene glycol complex, aluminium dichlorohydrex propylene glycol complex, aluminium sesquichlorohydrate, aluminium sesquichlorohydrex polyethylene glycol complex, aluminium sesquichlorohydrex propylene glycol complex, aluminium sulfate buffered by sodium aluminium lactate. Among the aluminum and zirconium salts, we can mention in particular aluminum zirconium octachlorohydrate, aluminum zirconium pentachlorohydrate, aluminum zirconium tetrachlorohydrate, aluminum zirconium trichlorohydrate. Zirconium hydroxychloride and aluminum hydroxychloride complexes with an amino acid are generally known as ZAGs (when the amino acid is glycine). Examples of these products include aluminum zirconium octachlorohydrex glycine, aluminum zirconium pentachlorohydrex glycine, aluminum zirconium tetrachlorohydrex glycine, and aluminum zirconium trichlorohydrex glycine. Aluminium sesquichlorohydrate is notably sold under the trade name REACH 301® by the company SUMMITREHEIS. Among the aluminium and zirconium salts, we can mention zirconium hydroxychloride and aluminium hydroxychloride complexes with an amino acid such as glycine, with the INCI name: ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY, for example, the one marketed under the name REACH AZP-908-SUF® by the company SUMMITREHEIS. Aluminium chlorohydrate will be used in particular in activated or non-activated form under the trade names LOCRON S FLA®, LOCRON P, LOCRON L.ZA by the company CLARIANT; under the trade names MICRODRY ALUMINUM CHLOROHYDRATE®, MICRO-DRY 323®, CHLORHYDROL 50, REACH 103, REACH 501 by the company SUMMITREHEIS; under the trade name WESTCHLOR 200® by the company WESTWOOD; under the trade name ALOXICOLL PF 40® by the company GUILINI CHEMIE; CLURON 50%® by the company INDUSTRIA QUIMICA DEL CENTRO; CLOROHIDROXIDO ALUMINIO SO A 50%® by the company FINQUIMICA. Another example of an antiperspirant active ingredient is expanded perlite particles such as those obtained by the expansion process described in US patent 5,002,698. Preferably, compositions A and / or B (or the ready-to-use composition or the single anhydrous composition) comprise less than 5% by weight of aluminium salt, preferably less than 3% by weight, preferably less than 1% by weight. Preferably, compositions A and / or B (or the ready-to-use composition or the single anhydrous composition) are totally free of aluminum salt. In the case where compositions A and B are mixed extemporaneously, the galenic forms will preferably be aqueous, alcoholic or hydroalcoholic solutions. AQUEOUS PHASE Compositions A and / or B (or the ready-to-use composition) may include at least one aqueous phase. They are notably formulated as aqueous lotions or as water-in-oil, oil-in-water, or multiple emulsions (triple oil-in-water-in-oil or water-in-oil-in-water emulsions (such emulsions are known and described for example by C. FOX in "Cosmetics and Toiletries" - November 1986 - Vol 101 - pages 101-112). The aqueous phase of said compositions A and / or B (or of the ready-to-use composition) contains water and generally other solvents soluble or miscible in water. Solvents soluble or miscible in water include short-chain monoalcohols, for example C1-C4 such as ethanol, isopropanol; diols or polyols such as ethylene glycol, 1,2-propylene glycol, 1,3-butylene glycol, hexylene glycol, diethylene glycol, dipropylene glycol, 2- ethoxyethanol, diethylene glycol monomethyl ether, triethylene glycol monomethyl ether, and sorbitol. Propylene glycol, glycerin, and propane 1,3-diol will be used more specifically. EMULSIONS a) Oil-in-water emulsifiers Compositions A and / or B (or the ready-to-use composition) may include at least one surfactant. Surfactants can be of all kinds commonly used in cosmetics, such as anionic surfactants, cationic surfactants, amphoteric surfactants or non-ionic surfactants. Preferably, non-ionic surfactants are used, such as: - C8-C30 (preferably C12-C18) polyoxyethylenated fatty alcohols, having in particular 2 to 100 moles of ethylene oxide, such as the oxyethylenated ether of cetearyl alcohol with 30 oxyethylenated groups (CTFA name "Ceteareth-30"), the oxyethylenated ether of stearyl alcohol with 20 oxyethylenated groups (CTFA name "Steareth-20") such as BRIJ 78 marketed by the company UNIQEMA, or the oxyethylenated ether of cetearyl alcohol with 33 oxyethylenated groups (CTFA name "Ceteareth-33"); - C8-C30 fatty alcohol and sugar ethers, in particular alkyl (C8-C30) (poly)glucosides, alone or in mixtures with alcohols, such as the mixture of cetostearyl alcohol and cocoglucoside marketed under the name MONTANOV 82® by Seppic, the mixture of arachidyl alcohol and behenyl alcohol with arachidylglucoside marketed under the name MONTANOV 802® by Seppic, the mixture of myristyl alcohol and myristylglucoside marketed under the name MONTANOV 14® by Seppic, the mixture of cetostearyl alcohol and cetostearylglucoside marketed under the name MONTANOV 68® by Seppic, the mixture of C14-C22 alcohol with C12-C20 alkylglucoside marketed under the name MONTANOV L® by Seppic, the mixture of cocoalcohol and cocoglucoside marketed under the name MONTANOV S® by Seppic or the mixture of isostearyl alcohol and isostearylglucoside marketed under the name MONTANOV WO 18® by Seppic; - polyethylene glycol ethers, having in particular 20 to 120 ethylene oxide units, and C8-C30 fatty acid esters and glucose or methylglucose, - C8-C30 fatty acid esters and sorbitan, - polyoxyethylenated C8-C30 fatty acid and sorbitan esters, notably containing 2 to 30 moles of ethylene oxide, - polyoxyethylenated esters of C8-C30 fatty acids and sorbitan, having in particular 2 to 100 moles of ethylene oxide, - mono- or diesters of C8-C30 fatty acids and glycerol, - polyglycerolized C8-C30 fatty acid esters, notably having 2 to 16 moles of glycerol, -C8-C30 fatty acid esters and polyethylene glycol, having in particular from 2 to 200 ethylene oxide units, - C8-C30 fatty acid esters of glucose or alkyl(C1-C2)glucose or sucrose, and - their mixtures. The surfactant(s) may be present in an amount ranging from 0.1 to 10% by weight, relative to the total weight of composition A or B (or the ready-to-use composition), preferably ranging from 0.2 to 5% by weight, and preferably ranging from 1% to 4% by weight. b) Water-in-oil emulsifiers Among the emulsifiers that can be used in water-in-oil emulsions or triple water-in-oil-in-water-in-oil emulsions, alkyl dimethicone copolyols corresponding to the following formula (I) may be cited as an example CH, I OH — o- ^3 Qi O Çh3 -Qi n- çh3 Qi OLJ UM3 Si Ol O ol LJ ol Ol iq I d ch3 R1 R ch3 a L 2 J b in which: Ri designates a linear or branched alkyl group in C12-C20 and preferably in C12-C18; R2 designates the group: -CnH2n-(-OC2H4-)x-(-OC3H6-)yO-R3, R3 designates a hydrogen atom or a linear or branched akyl radical containing from 1 to 12 carbon atoms; a is an integer ranging from 1 to approximately 500; b denotes an integer ranging from 1 to approximately 500; n is an integer ranging from 2 to 12 and preferably from 2 to 5; x represents an integer ranging from 1 to approximately 50 and preferably from 1 to 30; y denotes an integer ranging from 0 to about 49 and preferably from 0 to 29 provided that when y is not zero the ratio x / y is greater than 1 and preferably varies from 2 to 11. Among the preferred alkyldimethicone copolyol emulsifiers of formula (I), special mention should be made of CETYL PEG / PPG-10 / 1 DIMETHICONE, and more specifically the mixture CETYL PEG / PPG-10 / 1 DIMETICONE AND DIMETHICONE (INCI name), such as the product sold under the trade name ABIL EM90 by GOLDSCHMIDT; LAURYL PEG / PPG-18 / 18 methicone, and more specifically the mixture LAURYL PEG / PPG-18 / 18 methicone and DODECENE and POLOXAMER 407, such as the product sold under the trade name DOW CORNING 5200 FORMULATION AID by DOW CORNING; or the mixture (Polyglyceryl-4-stearate and Cetyl PEG / PPG-10 (and) Dimethicone (and) Hexyl Laurate), such as the product sold under the trade name ABIL WE09 by the GOLDSCHMIDT company. Among water-in-oil emulsifiers, we can also mention dimethicone copolyols corresponding to the following formula (II): CH, I CH — c" ^H3 CS O ÇH3 -Qi n- ÇH3 ci nu Si Ol '-J ol LJ ol Ol I ch3 ch3 R4 CFI3 cd (H) in which R4 designates the group: -CmH2m-(-OC2H4-)s-(-OC3H6-)tO-R5, R5 designates a hydrogen atom or a linear or branched akyl radical containing from 1 to 12 carbon atoms; It is an integer ranging from 1 to approximately 500. d denotes an integer ranging from 1 to approximately 500, m is an integer ranging from 2 to 12 and preferably from 2 to 5, s denotes an integer ranging from 1 to approximately 50, and preferably from 1 to 30; t denotes an integer ranging from 0 to about 50 and preferably from 0 to 30; provided that the sum s+t is greater than or equal to 1. Among these preferred formula (II) dimethicone copolyol emulsifiers, PEG-18 / PPG-18 DIMETHICONE will be used in particular, and more specifically the mixture CYCLOPENTASILOXANE (and) PEG-18 / PPG-18 DIMETHICONE (INCI name) such as the product sold by Dow Corning under the trade name Silicone DC 5225 C or KF-6040 by Shin Etsu. In a particularly preferred form, a mixture of at least one emulsifier of formula (I) and at least one emulsifier of formula (II) will be used. In particular, we will use a mixture of PEG-18 / PPG-18 Dimethicone and Cetyl PEG / PPG-10 / 1 DIMETHICONE, LAURYL PEG / PPG-18 / 18 methicone and even more particularly a mixture of (CYCLOPENTASILOXANE (and) PEG-18 / PPG-18 Dimethicone) and Cetyl PEG / PPG-10 / 1 DIMETICONE and Dimethicone or (Polyglyceryl-4-stearate and Cetyl PEG / PPG-10 (and) Dimethicone (and) Hexyl Laurate) or the mixture of LAURYL PEG / PPG-18 / 18 methicone and DODECENE and POLOXAMER 407. Among water-in-oil emulsifiers, we can also mention non-ionic emulsifiers derived from fatty acids and polyols, alkyl polyglycosides (APGs), sugar esters and their mixtures. As non-ionic emulsifiers derived from fatty acids and polyols, fatty acid and polyol esters can be used, the fatty acid having in particular an alkyl chain in C8-C24, and the polyols being for example glycerol and sorbitan. Examples of fatty acid and polyol esters include isostearic acid and polyol esters, stearic acid and polyol esters, and their mixtures, in particular isostearic acid esters and glycerol and / or sorbitan. Examples of esters of stearic acid and polyols include polyethylene glycol esters such as PEG-30 Dipolyhydroxystearate, such as the product marketed under the name Arlacel P135 by the company ICI. Examples of glycerol and / or sorbitan esters include polyglycerol isostearate, such as the product marketed under the name Isolan Gl 34 by Goldschmidt; sorbitan isostearate, such as the product marketed under the name Arlacel 987 by ICI; sorbitan isostearate and glycerol, such as the product marketed under the name Arlacel 986 by ICI; the mixture of sorbitan isostearate and polyglycerol isostearate (3 moles) marketed under the name Arlacel 1690 by Unigema; and mixtures thereof. The emulsifier can also be chosen from alkyl polyglycosides having an HLB less than 7, for example those represented by the following general formula (1): RO-(G)x (1) in which R represents a branched and / or unsaturated alkyl radical, comprising 14 to 24 carbon atoms, G represents a reduced sugar comprising 5 to 6 carbon atoms, and x designates a value from 1 to 10 and preferably from 1 to 4, and G designates in particular glucose, fructose or galactose. The unsaturated alkyl radical may include one or more ethylenic unsaturations, and in particular one or two ethylenic unsaturations. Examples of alkylpolyglycosides of this type include alkylpolyglucosides (G=glucose in formula (1)), and in particular compounds of formula (I) in which R represents more specifically an oleyl radical (unsaturated radical at C18) or isostearyl radical (saturated radical at C18), G designates glucose, x is a value from 1 to 2, notably isostearyl-glucoside, oleyl-glucoside and their mixtures. This alkylpolyglucoside can be used in a mixture with a co-emulsifier, more specifically with a fatty alcohol and in particular a fatty alcohol having the same fatty chain as the alkylpolyglucoside, i.e. having 14 to 24 carbon atoms and having a branched and / or unsaturated chain, and for example isostearyl alcohol when the alkylpolyglucoside is isostearyl-glucoside, and oleyl alcohol when the alkylpolyglucoside is oleyl-glucoside, possibly in the form of a self-emulsifying composition, as described for example in document WO-A-92 / 06778.For example, one can use the mixture of isostearyl glucoside and isostearyl alcohol, marketed under the name Montanov WO 18 by the company SEPPIC, as well as the mixture of octyldodecanol and octyldodecylxyloside marketed under the name FLUDANOV 20X by the company SEPPIC. We can also mention succin-terminated polyolefins, such as esterified succin-terminated polyisobutylenes and their salts, particularly diethanolamine salts, such as the products marketed under the the names Lubrizol 2724, Lubrizol 2722 and Lubrizol 5603 by the company Lubrizol or the commercial product CHEMCINNATE 2000. The total quantity of emulsifier(s) in composition A or B (or in the ready-to-use composition) will preferably be at active matter contents ranging from 1 to 8% by weight and more particularly from 2 to 6% by weight relative to the total weight of the composition. According to a particular embodiment of the invention, compositions A and / or B (or the ready-to-use composition) in emulsion form can be prepared using the phase inversion manufacturing technique. This technique is, in principle, well known and notably described in the article "Phase Inversion Emulsification" by Th Förster et al., published in Cosmetics & Toiletries, vol. 106, December 1991, pp. 49-52. Its principle is as follows: (i) In the presence of a suitable emulsifying system, a fatty phase on the one hand and an aqueous phase on the other hand are mixed under agitation, said mixing being carried out at a temperature above the phase inversion temperature (PIT) of the medium, so as to obtain a water-in-oil type emulsion. (ii) The temperature of the emulsion thus obtained is brought down to a temperature lower than said phase inversion temperature, thereby obtaining an ultrafine oil-in-water type emulsion. (iii) Mineral nanopigments are introduced during the implementation of step (i) and / or at the end of step (ii). Suitable systems are non-ionic type emulsifiers and are selected from polyoxyethylenated and / or polyoxypropylenated fatty alcohols (i.e. compounds obtained by reaction between an aliphatic fatty alcohol, such as behenic alcohol or cetyl alcohol, with ethylene oxide or propylene oxide or a mixture of ethylene oxide / propylene oxide) and esters of fatty acids and polyols, possibly polyoxyethylenated and / or polyoxypropylenated (i.e. compounds obtained by reaction of a fatty acid, such as stearic acid or oleic acid, with a polyol, such as alkylene glycol or glycerol or polyglycerol, possibly in the presence of ethylene oxide or propylene oxide or a mixture of ethylene oxide / propylene oxide), or mixtures thereof. Furthermore, and preferably, the selected emulsifying system will have an overall HLB (HLB = Hydrophilic-Lipophilic Balance, in the sense of Griffin; see J. Soc. Cosm. Chem. 1954 (vol 5), pp 249-256; balance between the hydrophilic character and the lipophilic character of the surfactant) ranging from approximately 9.5 to 11.5, advantageously close to 10, so as to allow the obtaining of a phase inversion at a temperature below 90°C (TIP<90°C). The content of emulsifying agent(s) is between 0.5 and 40% by weight and preferably between 2 and 10% by weight relative to the total weight of the emulsion. FAT PHASE Compositions A and / or B (or the ready-to-use composition or the single anhydrous composition) may contain at least one water-immiscible organic liquid phase called the oil phase. This generally comprises one or more hydrophobic compounds that render the phase immiscible in water. The phase is liquid (in the absence of a structuring agent) at temperature ambient (20-25 °C). Preferably, the water-immiscible organic liquid phase according to the invention is generally constituted and generally comprises at least one volatile oil and / or one non-volatile oil and optionally at least one structuring agent. The term "oil" refers to a liquid fat at room temperature (25°C) and atmospheric pressure (760 mmHg or 105 Pa). Oil can be volatile or non-volatile. For the purposes of this invention, "volatile oil" means an oil capable of evaporating upon contact with the skin or keratin fiber in less than one hour, at ambient temperature and atmospheric pressure. The volatile oils of the invention are volatile cosmetic oils, liquid at ambient temperature, having a non-zero vapor pressure, at ambient temperature and atmospheric pressure, ranging in particular from 0.13 Pa to 40,000 Pa (10⁻³ to 300 mm Hg), in particular ranging from 1.3 Pa to 13,000 Pa (0.01 to 100 mm Hg), and more particularly ranging from 1.3 Pa to 1300 Pa (0.01 to 10 mm Hg). By "non-volatile oil" we mean an oil that remains on the skin or keratin fiber at room temperature and atmospheric pressure for at least several hours and has in particular a vapor pressure of less than 10'3 mm of Hg (0.13 Pa). The oil can be chosen from all physiologically acceptable oils and in particular cosmetically acceptable oils, including mineral, animal, vegetable, synthetic oils; in particular volatile or non-volatile hydrocarbon and / or silicone and / or fluorinated oils and their mixtures. More precisely, "hydrocarbon oil" refers to an oil composed primarily of carbon and hydrogen atoms and possibly one or more functional groups selected from among the hydroxyl, ester, ether, and carboxylic groups. Generally, the oil has a viscosity of 0.5 to 100,000 mPa·s, preferably 50 to 50,000 mPa·s, and even more preferably 100 to 300,000 mPa·s. Examples of volatile oils that can be used in the invention include: Volatile hydrocarbon oils selected from among hydrocarbon oils having 8 to 16 carbon atoms, and in particular petroleum-derived Cs-Ci6 isoalkanes (also called isoparaffins) such as isododecane (also known as 2,2,4,4,6-pentamethylheptane), isodecane, isohexadecane, and for example, oils sold under the trade names Isopars or Permetyls, C8-Ci6 branched esters, isohexyl neopentanoate, and mixtures thereof. Other volatile hydrocarbon oils such as petroleum distillates, particularly those sold under the Shell brand by Shell, may also be used; volatile linear alkanes such as those described in Cognis patent application DE10 2008 012 457. Volatile silicones, such as volatile linear or cyclic silicone oils, particularly those with a viscosity < 8 centistokes (8 x 10⁶ m² / s), and containing from 2 to 7 silicon atoms, these silicones optionally comprising alkyl or alkoxy groups having from 1 to 10 carbon atoms. Examples of volatile silicone oils usable in the invention include octamethyl cyclotetrasiloxane, decamethyl cyclopentasiloxane, dodecamethyl cyclohexasiloxane, heptamethyl hexyltrisiloxane, heptamethyloctyl trisiloxane, hexamethyl disiloxane, octamethyl trisiloxane, decamethyl tetrasiloxane, and dodecamethyl pentasiloxane. and their mixtures. We can also mention volatile linear alkyltrisiloxane oils with general formula (I): CH 3 CHj —SiO—Si O Si CH^ \ 13 \ il \ 1 \ / 3 R where R represents an alkyl group comprising 2 to 4 carbon atoms and of which one or more hydrogen atoms may be substituted by a fluorine or chlorine atom. Among the oils of general formula (I), we can mention: 3-butyl 1,1,1,3,5,5,5-heptamethyl trisiloxane, 3-propyl 1,1,1,3,5,5,5-heptamethyl trisiloxane, and 3-ethyl 1,1,1,3,5,5,5-heptamethyl trisiloxane, corresponding to the oils of formula (I) for which R is respectively a butyl group, a propyl group or an ethyl group. Examples of non-volatile oils usable in the invention include: vegetable hydrocarbon oils such as liquid triglycerides of fatty acids with 4 to 24 carbon atoms, like heptanoic or octanoic acid triglycerides, or wheat germ oil, olive oil, sweet almond oil, palm oil, rapeseed oil, cottonseed oil, coconut oil, alfalfa oil, poppy oil, pumpkin seed oil, squash oil, blackcurrant oil, evening primrose oil, millet oil, barley oil, quinoa oil, rye oil, safflower oil, candlenut oil, passionflower oil, rosehip oil, sunflower oil, corn oil, soybean oil, pumpkin seed oil, grape seed oil, sesame oil, hazelnut oil, apricot kernel oil, macadamia nut oil, castor oil, avocado oil, and caprylic / capric acid triglycerides such as those sold by Stearineries Dubois. those sold under the names Miglyol 810, 812 and 818 by the company SASOL, jojoba oil, shea butter; linear or branched hydrocarbons, of mineral or synthetic origin such as paraffin oils and their derivatives, petroleum jelly, polydecenes, polybutenes, hydrogenated polyisobutene such as Parleam, squalane; synthetic ethers having 10 to 40 carbon atoms; synthetic esters, particularly of fatty acids, such as oils with the formula R1COOR2, in which Ri represents the remainder of a higher linear or branched fatty acid containing 1 to 40 carbon atoms, and R2 represents a hydrocarbon chain, particularly a branched one, containing 1 to 40 carbon atoms, with Ri + R2 > 10, such as Purcellin oil (octanoate of cetostearyl), isononyl isononanoate, isopropyl myristate, isopropyl palmitate, C12-C15 alcohol benzoate, hexyl laurate, diisopropyl adipate, isononyl isononanoate, ethyl 2-hexyl palmitate, octyl 2-dodecyl stearate, octyl 2-dodecyl erucate, isostearyl isostearate, tridecyl trimellitate; octanoates, decanoates or ricinoleates of alcohols or polyalcohols such as propylene glycol dioctanoate; hydroxylated esters such as isostearyl lactate, octyl hydroxy stearate, octyl dodecyl hydroxy stearate, diisostearyl malate, triisocetyl citrate, heptanoates, octanoates, decanoates of fatty alcohols; polyol esters such as propylene glycol dioctanoate, neopentyl glycol diheptanoate, diethylene glycol diisononanoate; and pentaerythritol esters such as pentaerythrytyl tetraisostearate; - liquid fatty alcohols at room temperature with branched and / or unsaturated carbon chains having 12 to 26 carbon atoms such as octyl dodecanol, isostearyl alcohol, 2-butyloctanol, 2-hexyl decanol, 2-undecyl pentadecanol, oleic alcohol; - higher fatty acids such as oleic acid, linoleic acid, linolenic acid; - fluorinated oils possibly partially hydrocarbon and / or siliconed such as fluorosilicone oils, fluorinated polyethers, fluorinated silicones as described in document EP-A-847752; - silicone oils such as non-volatile, linear or cyclic polydimethylsiloxanes (PDMS); polydimethylsiloxanes containing alkyl, alkoxy or phenyl groups, during or at the end of the silicone chain, groups having from 2 to 24 carbon atoms; phenyl silicones such as phenyl trimethicones, phenyl dimethicones, phenyl trimethylsiloxy diphenyl siloxanes, diphenyl dimethicones, diphenyl methyldiphenyl trisiloxanes, 2-phenyl ethyl trimethyl-siloxysilicates, and their mixtures. solid fats Compositions A and / or B (or the ready-to-use composition or the single anhydrous composition) may include at least one solid fat body, preferably chosen from waxes and pasty fats, and mixtures thereof, and more particularly waxes. Pasty fats For the purposes of this invention, "pasty fat" (also called pasty fat) means a lipophilic fatty compound with reversible solid / liquid phase change, exhibiting anisotropic crystalline organization in the solid state, and comprising at a temperature of 23 °C a liquid fraction and a solid fraction. In other words, the initial melting temperature of the paste compound can be below 23°C. The liquid fraction (cb) of the paste compound measured at 23°C can represent 9% to 97% by weight of the compound. This liquid fraction at 23°C preferably represents between 15% and 85%, and even more preferably between 40% and 85% by weight. For the purposes of this invention, the melting temperature corresponds to the temperature of the most endothermic peak observed in thermal scanning calorimetry (DSC) as described in ISO 11357-3:1999. The melting point of a paste or of a wax can be measured using a differential scanning calorimeter (DSC), for example the calorimeter sold under the name "MDSC 2920" by the company 45 TA Instruments. The measurement protocol is as follows: a 5 mg sample of paste or wax (as appropriate) placed in a crucible is subjected to an initial heating from -20 °C to 100 °C at a rate of 10 °C / minute, then cooled from 100 °C to -20 °C at a rate of 10 °C / minute, and finally subjected to a second heating from -20 °C to 100 °C at a rate of 5 °C / minute. During this second heating, the variation in the difference in power absorbed by the empty crucible and by the crucible containing the paste or wax sample is measured as a function of temperature. The melting point of the compound is the temperature value corresponding to the peak of the curve representing the variation of the difference in absorbed power as a function of temperature. The liquid fraction by weight of the pasty compound at 23 °C is equal to the ratio of the enthalpy of fusion consumed at 23 °C to the enthalpy of fusion of the pasty compound. The enthalpy of fusion of a paste-like compound is the enthalpy consumed by the compound to change from a solid to a liquid state. A paste-like compound is said to be in a solid state when its entire mass is in crystalline solid form. A paste-like compound is said to be in a liquid state when its entire mass is in liquid form. The enthalpy of fusion of the paste-like compound is equal to the area under the curve of the thermogram obtained using a differential scanning calorimeter (DSC), such as the calorimeter sold under the name MDSC 2920 by TA Instrument, with a temperature rise of 5 °C or 10 °C per minute, according to ISO 11357-3:1999. The enthalpy of fusion of the paste-like compound is the amount of energy required to change the compound from a solid to a liquid state. It is expressed in J / g. The enthalpy of fusion consumed at 23 °C is the amount of energy absorbed by the sample to change from a solid state to its state at 23 °C, consisting of a liquid fraction and a solid fraction. The liquid fraction of the paste-like compound measured at 32 °C preferably represents 30% to 100% by weight of the compound, preferably 50% to 100%, and preferably 60% to 100% by weight of the compound. When the liquid fraction of the paste-like compound measured at 32 °C is equal to 100%, the temperature at the end of the melting range of the paste-like compound is less than or equal to 32 °C. The liquid fraction of the paste-like compound measured at 32 °C is equal to the ratio of the enthalpy of fusion consumed at 32 °C to the enthalpy of fusion of the paste-like compound. The enthalpy of fusion consumed at 32 °C is calculated in the same way as the enthalpy of fusion consumed at 23 °C. The paste-like compound is preferably chosen from synthetic compounds and compounds of plant origin. A paste-like compound can be obtained synthetically from starting materials of plant origin. The paste-like compound is advantageously chosen from: - lanolin and its derivatives; - polyol ethers selected from pentaerythritol and polyalkylene glycol ethers, fatty alcohol and sugar ethers, and mixtures thereof, pentaerythritol and polyethylene glycol ether containing 5 oxyethylenated units (5 EOs) (CTFA name: PEG-5 Pentaerythrityl Ether), pentaerythritol and polypropylene glycol ether containing 5 oxypropylenated units (5 OPs) (CTFA name: PPG-5 Pentaerythrityl Ether), and mixtures thereof, and more specifically the mixture of PEG-5 Pentaerythrityl Ether, PPG-5 Pentaerythrityl Ether and soybean oil, marketed under the name "Lanolide" by the Vevy company, a mixture in which the constituents are in a weight ratio of 46 / 46 / 8: 46% PEG-5 Pentaerythrityl Ether, 46% PPG-5 Pentaerythrityl Ether and 8% soybean oil; - silicone compounds, polymeric or not; - fluorinated compounds, polymeric or not; - vinyl polymers, in particular homopolymers and copolymers of olefins, homopolymers and copolymers of hydrogenated dienes, linear or branched oligomers, homo or copolymers of alkyl (meth)acrylates preferably having an alkyl group at C8-C30, homo oligomers and copolymers of vinyl esters having alkyl groups at C8-C30, homo oligomers and copolymers of vinyl ethers having alkyl groups at C8-C30; - liposoluble polyethers resulting from polyetherification between one or more diols in C2-C100, preferably in C2-C50; - esters; - and / or mixtures thereof. The paste-like compound is preferably a polymer, in particular a hydrocarbon. Among the liposoluble polyethers, copolymers of ethylene oxide and / or propylene oxide with long-chain C6-C30 alkylene oxides are preferred in particular, preferably such that the weight ratio of ethylene oxide and / or propylene oxide with alkylene oxides in the copolymer is 5:95 to 70:30. In this family, we will mention in particular copolymers such as long chain alkylene oxides arranged in blocks having an average molecular weight of 1000 to 10000, for example a polyoxyethylene / polydodecyl glycol block copolymer such as dodecanediol ethers (22 mol) and polyethylene glycol (45 OE) marketed under the brand ELFACOS ST9 by Akzo Nobel. Among the esters, the following are particularly preferred: - the esters of an oligomeric glycerol, in particular diglycerol esters, especially adipic acid and glycerol condensates, in which part of the hydroxyl groups of the glycerols have reacted with a mixture of fatty acids such as stearic acid, capric acid, stearic acid and isostearic acid and 12-hydroxystearic acid, in particular those marketed under the Softisan 649 brand by the company Sasol; - arachidyl propionate marketed under the brand name Waxenol 801 by Alzo; - phytosterol esters; - fatty acid triglycerides and their derivatives; - pentaerythritol esters; - non-crosslinked polyesters resulting from polycondensation between a C4-C50 linear or branched dicarboxylic acid or polycarboxylic acid and a C2-C50 diol or polyol; - aliphatic esters of esters resulting from the esterification of an aliphatic hydroxycarboxylic acid ester by an aliphatic carboxylic acid. Preferably, the aliphatic carboxylic acid comprises from 4 to 30 and preferably from 8 to 30 carbon atoms. It is preferably chosen from hexanoic acid, heptanoic acid, octanoic acid, 2-ethylhexanoic acid, nonanoic acid, decanoic acid, undecanoic acid, dodecanoic acid, tridecanoic acid, tetradecanoic acid, pentadecanoic acid, hexadecanoic acid, hexyldecanoic acid, heptadecanoic acid, octadecanoic acid, isostearic acid, nonadecanoic acid, eicosanoic acid, isoarachidic acid, octyldodecanoic acid, heneicosanoic acid, docosanoic acid, and mixtures thereof. The aliphatic carboxylic acid is preferably branched.The aliphatic hydroxycarboxylic acid ester is advantageously derived from a hydroxylated aliphatic carboxylic acid having from 2 to 40 carbon atoms, preferably from 10 to 34 carbon atoms and better from 12 to 28 carbon atoms, and from 1 to 20 hydroxyl groups, preferably from 1 to 10 hydroxyl groups and better from 1 to 6 hydroxyl groups. The aliphatic hydroxycarboxylic acid ester is notably chosen from: a) partial or total esters of linear, saturated, monohydroxylated, linear aliphatic monocarboxylic acids; b) partial or total esters of unsaturated monohydroxylated aliphatic monocarboxylic acids; c) partial or total esters of saturated monohydroxylated aliphatic polycarboxylic acids; d) partial or total esters of saturated polyhydroxylated aliphatic polycarboxylic acids; e) partial or total esters of C2 to C16 aliphatic polyols that have reacted with a mono or poly aliphatic carboxylic acid that is mono or poly hydroxylated, and mixtures thereof; - diol and diacid dimer esters, where appropriate, esterified on their free alcohol or acid function(s) by acid or alcohol radicals, in particular dimer dilinoleate esters, such esters may be chosen in particular from the following INCI nomenclature esters: bisbehenyl / isostearyl / phytosteryl dimerdilinoleyl dimerdilinoleate (Plandool G), phytosteryl / isosteryl / cetyl / stearyl / behenyl dimerdilinoleate (Plandool H or Plandool 40 S), and mixtures thereof; - hydrogenated rosinate esters, such as hydrogenated rosinate dilinoyl dimers (Lusplan DD-DHR or DD-DHR from Nippon Fine Chemical); and - their mixtures. Waxes According to a preferred embodiment, composition A and / or B (or the ready-to-use composition or the single anhydrous composition) comprises at least one wax. The wax considered within the scope of the present invention is generally a lipophilic compound, solid at room temperature (25 °C), with a reversible solid / liquid phase change, having a melting point greater than or equal to 30 °C, up to 200 °C, and in particular up to 120 °C. In particular, waxes suitable for the invention may have a melting point greater than or equal to 45 °C, and in particular greater than or equal to 55 °C. The waxes that may be used in compositions A and / or B (or the composition ready-to-use) are chosen from waxes, solid, at room temperature, of animal, vegetable, mineral or synthetic origin and their mixtures. Examples include the following hydrocarbon waxes comprising a fatty alkyl chain generally having 10 to 60 carbon atoms, preferably 20 to 40 carbon atoms, said chain being able to be saturated or unsaturated, substituted or unsubstituted, linear, branched or cyclic, preferably saturated and linear: - fatty alcohols; - fatty alcohol esters; - fatty acids; - fatty acid amides; - fatty acid esters including triglycerides; - fatty acid ethers; - ethoxylated fatty alcohols; - ethoxylated fatty acids, and their corresponding salts. Among fatty alcohols, we can mention stearyl alcohol, cetearyl alcohol or mixtures thereof. Examples of fatty alcohol esters include tri-isostearyl citrate, ethylene glycol-di-12-hydroxystearate, tristearyl citrate, stearyl octanoate, stearyl heptanoate, trilauryl citrate, and mixtures thereof. Examples of fatty acid esters include ester waxes, monoglycerides, diglycerides, and triglycerides. Examples of ester waxes include stearyl stearate, stearyl behenate, stearyl octyldodecanol, cetearyl behenate, behenyl behenate, ethylene glycol, distearate, and ethylene glycol dimaplimitate. In particular, a C20-C40 alkyl (hydroxystearyloxy)stearate (with the alkyl group comprising 20 to 40 carbon atoms) can be used, either alone or in mixtures. Such a wax is notably sold under the names "Kester Wax K 82 P®", "Hydroxypolyester K 82 P®" and "Kester Wax K 80 P®" >> by the company Koster Keunen. Among the triglyceride waxes, we can mention in particular tribehenin, C18-C36 triglyceride, and their mixtures. By way of illustration of waxes suitable for the invention, one may mention in particular hydrocarbon waxes such as beeswax, lanolin wax, and insect waxes, China wax, rice bran wax, carnauba wax, candelilla wax, ouricury wax, alfa wax, berry wax, shellac wax, Japanese wax and sumac wax, montan wax, orange and lemon waxes, microcrystalline waxes, paraffins and ozokerite, polyethylene waxes, waxes obtained by Fisher-Tropsch synthesis, and waxy copolymers as well as their esters. We can also mention waxes obtained by catalytic hydrogenation of animal or vegetable oils having linear or branched fatty chains, in C8-C32. Among these, we can notably mention isomerized jojoba oil such as partially hydrogenated isomerized trans jojoba oil manufactured or marketed by the company Desert Whale under the trade reference iso-Jojoba-50®, hydrogenated sunflower oil, hydrogenated castor oil, hydrogenated coconut oil, hydrogenated lanolin oil, and di-(trimethylol-1,1,1-propane tetrastearate) sold under the name Hest 2T-4S® by the company Heterene. Other examples include silicone waxes (C30-45 Alkyl dimethicone) and fluorinated waxes. Waxes obtained by hydrogenating esterified castor oil with cetyl alcohol, sold under the names Phytowax ricin 16L64® and 22L73® by the company Sophim, can also be used. Such waxes are described in particular in French patent application FR 2 792 190. Examples of micro-waxes that can be used in compositions A and / or B include carnauba micro-waxes such as that marketed under the name MicroCare 350® by Micro Powders, synthetic wax micro-waxes such as that marketed under the name MicroEase 114S® by Micro Powders, micro-waxes made from a mixture of carnauba wax and polyethylene wax such as those marketed under the names Micro Care 300® and 310® by Micro Powders, micro-waxes made from a mixture of carnauba wax and synthetic wax such as that marketed under the name Micro Care 325® by Micro Powders, and polyethylene micro-waxes such as those marketed under the names Micropoly 200®, 220®,220L® and 250S® by Micro Powders and polytetrafluoroethylene micro-waxes such as those marketed under the names Microslip 519® and 519 L® by Micro Powders. Composition A and / or B (or the ready-to-use composition or the single anhydrous composition) may include a solid fat content preferably ranging from 1% to 30% by weight, and in particular from 2% to 20% by weight relative to the total weight of the composition. ADDITIVES Compositions A and / or B (or the ready-to-use composition or the single anhydrous composition) may also include additional cosmetic active ingredients. Cosmetic compositions A and / or B (or the ready-to-use composition or the single anhydrous composition) may further include cosmetic adjuvants selected from opacifiers, stabilizers, preservatives, perfumes, sunscreens, cosmetic actives, fillers, suspending agents, sequestrants, coloring materials or any other ingredient commonly used in cosmetics for this type of application. Of course, the person skilled in the art will take care to choose this or these possible complementary compounds in such a way that the advantageous properties intrinsically attached to composition A or B or to the ready-to-use composition or to the single anhydrous composition, are not, or substantially not, altered by the envisaged addition(s). ORGANIC POWDER According to a particular embodiment of the invention, compositions A and / or B (or the ready-to-use composition or the single anhydrous composition) will also contain an organic powder. In this application, "organic powder" means any solid that is insoluble in the medium at room temperature (25°C). Examples of organic powders that can be used include polyamide particles, particularly those sold under the name ORGASOL by the company Atochem; nylon 6.6 fibers, particularly polyamide fibers marketed by Etablissements P Bonte under the name Polyamide 0.9 Dtex 0.3 mm (non-INCI: Nylon 6.6 or Polyamide-6.6) with an average diameter of 6 µm, a weight of approximately 0.9 dtex and a length ranging from 0.3 mm to 1.5 mm; polyethylene powders; microspheres based on acrylic copolymers, such as those made of ethylene glycol dimethacrylate / lauryl methacrylate copolymer sold by the company Dow Corning under the name POLYTRAP; methyl polymethacrylate microspheres, marketed under the name MICROSPHERE M-100 by Matsumoto or under the name COVABEAD LH85 by Wackherr;hollow polymethyl methacrylate microspheres (particle size: 6.5-10.5 µm) marketed under the name GANZPEARL GMP 0800 by Ganz Chemical; methyl methacrylate / ethylene glycol dimethacrylate copolymer microbeads (size: 6.5-10.5 µm) marketed under the name GANZPEARL GMP 0820 by Ganz Chemical or MICROSPONGE 5640 by Amcol Health & Beauty Solutions; ethylene-acrylate copolymer powders, such as those marketed under the name FLOBEADS by Sumitomo Seika Chemicals;expanded powders such as hollow microspheres and in particular, microspheres formed from a terpolymer of vinylidene chloride, acrylonitrile and methacrylate and marketed under the name EXPANCEL by the company Kemanord Plast under the references 551 DE 12 (particle size of about 12 pm and density 40 kg / m3), 551 DE 20 (particle size of about 30 pm and density 65 kg / m3), 551 DE 50 (particle size of about 40 pm), or microspheres marketed under the name MICROPEARL F 80 ED by the company Matsumoto; powders of natural organic materials such as starch powders, including corn, wheat or rice starches, crosslinked or not, such as starch powders crosslinked by octenylsuccinate anhydride, marketed under the name DRY-FLO by the company National Starch;silicone resin microbeads such as those marketed under the name TOSPEARL by Toshiba Silicone, in particular TOSPEARL 240; amino acid powders such as Lauroyllysine powder marketed under the name AMIHOPE LL-11 by Ajinomoto;Wax microdispersion particles, preferably having average dimensions of less than 1 µm and in particular ranging from 0.02 µm to 1 µm, and consisting essentially of a wax or a mixture of waxes, such as the products marketed under the name Aquacer by Byk Cera, and in particular: Aquacer 520 (mixture of synthetic and natural waxes), Aquacer 514 or 513 (polyethylene wax), Aquacer 511 (polymer wax), or such as the products marketed under the name Jonwax 120 by Johnson Polymer (mixture of polyethylene and paraffin waxes) and under the name Ceraflour 961 by Byk Cera (micronized modified polyethylene wax); and mixtures thereof. HYDROPHILIC THICKENERS According to an advantageous embodiment, composition A and / or B (or the ready-to-use composition) may further comprise at least one thickener. Such a thickener is preferably soluble or dispersible in water. Thickeners can be of natural or synthetic origin, mineral or organic. Thickeners will preferably be anionic, zwietrionic, non-ionic polymers, associative or non-associative. Thickeners can be chosen from cellulosic derivatives such as hydroxyethylcellulose; polysaccharides and especially gums such as xanthan gum, sclerotium gum. Associative polyurethanes are non-ionic sequenced copolymers comprising in the chain both hydrophilic sequences of most often polyoxyethylenated nature (the polyurethanes can then be called polyether polyurethanes) and hydrophobic sequences which can be aliphatic chains alone and / or cycloaliphatic and / or aromatic chains. In particular, these polymers comprise at least two lipophilic hydrocarbon chains, having from 6 to 30 carbon atoms, separated by a hydrophilic sequence. The hydrocarbon chains may be dangling chains or end chains of the hydrophilic sequence. Specifically, one or more dangling chains may be provided. Furthermore, the polymer may have a hydrocarbon chain at one or both ends of a hydrophilic sequence. Associative polyurethanes can be sequenced as triblocks or multiblocks. The hydrophobic sequences can therefore be located at each end of the chain (e.g., a triblock copolymer with a hydrophilic central sequence) or distributed both at the ends and throughout the chain (e.g., a multiblock copolymer). These polymers can also be in graft or star configurations. Preferably, associative polyurethanes are triblock copolymers whose hydrophilic sequence is a polyoxyethylenated chain containing 50 to 1000 oxyethylenated groups. Generally, associative polyurethanes contain a urethane bond between the hydrophilic sequences, hence the name. According to one embodiment, a non-ionic associative polymer of the polyurethane type is used as a gelling agent. Examples of non-ionic fat-chain polyurethane polyethers usable in the invention include Rhéolate® FX 1100 or Rheoluxe® 811 (Steareth-100 / PEG-136 / HDI(hexamethyl diisocyanate) copolymer), Rhéolate® 205 with urea function sold by ELEMENTIS, or Rhéolates® 208, 204 or 212, as well as Acrysol RM 184® or Acrysol RM 2020. We can also mention the ELFACOS T210® product with a C12-C14 alkyl chain and the ELFACOS T212® product with a C16-18 alkyl chain (PPG-14 Palmeth-60 Hexyl Dicarbamate) from AKZO. The product DW 1206B® from ROHM & HAAS, with a C20 alkyl chain and urethane bond, offered at 20% dry matter in water, can also be used. Solutions or dispersions of these polymers can also be used, particularly in water or hydroalcoholic solutions. Examples of such polymers include RHEOLATE® 255, RHEOLATE® 278, and RHEOLATE® 244, sold by ELEMENTIS. DW 1206F and DW 1206J, offered by ROHM & HAAS, are also available. The associative polyurethanes usable according to the invention are in particular those described in the article by G. Fonnum, J. Bakke and Fk. Hansen - Colloid Polym. Sci 271,380,389 (1993). An associative polyurethane can also be used, which can be obtained by polycondensation of at least three compounds comprising (i) at least one polyethylene glycol comprising 150 to 180 moles of ethylene oxide, (ii) stearyl alcohol or decyl alcohol and (iii) at least one diisocyanate. Such polyether polyurethanes are sold in particular by the company ROHM & HAAS under the names ACULYN 46® and ACULYN 44® [ACULYN 46® is a polyethylene glycol polycondensate with 150 or 180 moles of ethylene oxide, stearyl alcohol and methylene bis(4-cyclohexyl-isocyanate) (SMDI), at 15% by weight in a matrix of maltodextrin (4%) and water (81%); ACULYN 44® is a polyethylene glycol polycondensate with 150 or 180 moles of ethylene oxide, decyl alcohol and methylene bis(4-cyclohexylisocyanate) (SMDI), at 35% by weight in a mixture of propylene glycol (39%) and water (26%)]. Solutions or dispersions of these polymers can also be used, particularly in water or hydroalcoholic solutions. Examples of such polymers include RHEOLATE FX1010®, RHEOLATE FX1035®, and RHEOLATE 1070® from ELEMENTIS, as well as RHEOLATE 255®, RHEOLATE 278®, and RHEOLATE 244®, also sold by ELEMENTIS. Other products that can be used include ACULYN 44, ACULYN 46®, DW 1206F®, and DW 1206J®, as well as Acrysol RM 184 from ROHM & HAAS, and BORCHI GEL LW 44® from BORCHERS, and mixtures thereof. Preferably, an associative non-ionic polyurethane polyether is used, such as that sold in particular by the company ELEMENTIS under the name RHEOLATE FX 1100® or RHEOLUXE 811®, which is a polycondensate of polyethylene glycol with 136 moles of ethylene oxide, polyoxyethylenated stearyl alcohol with 100 moles of ethylene oxide and hexamethylene diisocyanate (HDI) having an average molecular weight by weight of 30000 (INCI name: Steareth-100 / PEG-136 / HDI Copolymer). Thickeners are generally present in composition A and / or B (or in the ready-to-use composition) in an active substance content ranging from 0% to 20% by weight, preferably ranging from 0% to 10% by weight, and most preferably ranging from 0% to 7% by weight, relative to the total weight of the composition. LIPOPHILE THICKENERS As a mineral lipophilic gelling agent, one can cite clays possibly modified such as hectorites modified by a C10 to C22 ammonium chloride, such as hectorite modified by di-stearyl di-methyl ammonium chloride such, for example, that marketed under the name Bentone 38V® by the company ELEMENTIS. We can also mention fumed silica, possibly with a hydrophobic surface treatment, whose particle size is less than 1 µm. It is indeed possible to chemically modify the surface of silica through a chemical reaction that reduces the number of silanol groups present on the silica surface. In particular, silanol groups can be replaced by hydrophobic groups, resulting in hydrophobic silica. These hydrophobic groups can be trimethylsiloxyl groups, which are obtained, notably, by treating fumed silica in the presence of hexamethyldisilazane. Silica treated in this way is called "Silica silylate" according to the CTFA (8th edition, 2000).For example, they are marketed under the references Aerosil R812® by DEGUSSA, and CAB-O-SIL TS-530® by CABOT. These are dimethylsilyloxyl or polydimethylsiloxane groups, obtained in particular by treating fumed silica in the presence of polydimethylsiloxane or dimethyldichlorosilane. Silicas treated in this way are called "Silica dimethyl silylate" according to the CTFA (8th edition, 2000). They are marketed, for example, under the references Aerosil R972® and Aerosil R974® by DEGUSSA, and CAB-O-SIL TS-610® and CAB-O-SIL TS-720® by CABOT. Hydrophobic pyrogenated silica in particular has a particle size that can be nanometric to micrometric, for example ranging from about 5 to 200 nm. Examples of polymeric organic lipophilic gelling agents include partially or fully cross-linked elastomeric organopolysiloxanes with a three-dimensional structure, such as those marketed under the names KSG6®, KSG16® and KSG18® by SHIN-ETSU, Trefil E-505C® and Trefil E-506C® by DOW-CORNING, Gransil SR-CYC®, SR DMF10®, SR-DC556®, SR 5CYC gel®, SR DMF 10 gel® and SR DC 556 gel® by GRANT INDUSTRIES, SF 1204® and JK 113® by GENERAL ELECTRIC; ethylcellulose such as that sold under the name Ethocel® by DOW CHEMICAL; galactomannans having from one to six, and in particular from two to four, hydroxyl groups per sugar, substituted by a saturated or unsaturated alkyl chain, such as guar gum alkylated by alkyl chains in C1 to C6, and in particular in C1 to C3 and their mixtures.Sequenced copolymers of the "dibloc", "tribloc" or "radial" type of polystyrene / polyisoprene, polystyrene / polybutadiene such as those marketed under the name Luvitol HSB® by BASF, of the polystyrene / copoly(ethylene-propylene) type such as those marketed under the name Kraton® by SHELL CHEMICAL CO or of the polystyrene / copoly(ethylene-butylene) type, mixtures of tribloc copolymers and . radial (star-shaped) in isododecane such as those marketed by PENRECO under the name Versagel® such as the mixture of triblock copolymer butylene / ethylene / styrene and star copolymer ethylene / propylene / styrene in isododecane (Versagel M 5960). As a lipophilic gelling agent, one can also cite polymers with a weight average molecular mass of less than 100,000, comprising a) a polymeric backbone having hydrocarbon repeat motifs provided with at least one heteroatom, and possibly b) at least one dangling fatty chain and / or at least one terminal fatty chain possibly functionalized, having from 6 to 120 carbon atoms and being linked to these hydrocarbon motifs, as described in applications WO-A-02 / 056847, WO-A-02 / 47619, in particular polyamide resins (including those comprising alkyl groups having from 12 to 22 carbon atoms) such as those described in US-A-5783657. Among the lipophilic gelling agents that can be used, we can also mention dextrin and fatty acid esters, such as dextrin palmitates, in particular those marketed under the names Rheopearl TL® or Rheopearl KL® by the company CHIBA FLOUR. One can also use silicone polyamides of the polyorganosiloxane type such as those described in documents US-A-5,874,069, US-A-5,919,441, US-A-6,051,216 and US-A-5,981,680. These silicone polymers can belong to the following two families: - polyorganosiloxanes comprising at least two groups capable of establishing hydrogen interactions, these two groups being located in the polymer chain, and / or - polyorganosiloxanes comprising at least two groups capable of establishing hydrogen interactions, these two groups being located on grafts or branches. SUSPENSION AGENTS Compositions A and / or B (or the ready-to-use composition or the single anhydrous composition) may also contain one or more suspending agents and / or one or more gelling agents. Some of these may perform both functions. Among the agents that can be used as suspending agents and / or lipophilic gelling agents are clays, in powder or oily gel form. These clays may be modified, including modified montmorillonite clays such as hydrophobic modified bentonites or hectorites, such as hectorites modified with C10 to C22 ammonium chloride, or hectorite modified with distearyldimonium chloride, for example, Disteardimonium Hectorite (CTFA name) (a reaction product of hectorite and distearyldimonium chloride) sold under the names Bentone 38 or Bentone Gel by Elementis Specialities. Another example is Stearalkonium Bentonite (CTFA name) (a reaction product of bentonite and quaternary ammonium chloride). of stearalkonium) such as the commercial product sold under the name TIXOGEL MP 250® by the company Sud Chemie Rheologicals, United Catalysts Inc. Hydrotalcites can also be used, in particular hydrophobic modified hydrotalcites such as the products sold under the name Gilugel by the company BK Giulini. We can also mention fumed silica, possibly with a hydrophobic surface treatment, whose particle size is less than 1 µm. It is indeed possible to chemically modify the surface of silica through a chemical reaction that reduces the number of silanol groups present on the silica surface. In particular, silanol groups can be replaced by hydrophobic groups, resulting in hydrophobic silica. These hydrophobic groups can be trimethylsiloxyl groups, which are obtained, notably, by treating fumed silica in the presence of hexamethyldisilazane. Silica treated in this way is called "Silica silylate" according to the CTFA (8th edition, 2000).For example, they are marketed under the references Aerosil R812® by DEGUSSA, and CAB-O-SIL TS-530® by CABOT. These are dimethylsilyloxyl or polydimethylsiloxane groups, obtained in particular by treating fumed silica in the presence of polydimethylsiloxane or dimethyldichlorosilane. Silicas treated in this way are called "Silica dimethyl silylate" according to the CTFA (8th edition, 2000). They are marketed, for example, under the references Aerosil R972® and Aerosil R974® by DEGUSSA, and CAB-O-SIL TS-610® and CAB-O-SIL TS-720® by CABOT. Hydrophobic pyrogenated silica in particular has a particle size that can be nanometric to micrometric, for example ranging from about 5 to 200 nm. According to a particular embodiment of the invention, the suspension or gelling agents can be activated by oils such as propylene carbonate, triethyl citrate. The quantities of these different constituents that may be present in composition A and / or B (or in the ready-to-use composition or the single anhydrous composition) are those classically used in compositions for the treatment of perspiration. Suspending agents are preferably present in quantities ranging from 0.1 to 5% by weight and more preferably from 0.2 to 2% by weight relative to the total weight of composition. The quantities of these different constituents that may be present in cosmetic compositions A and / or B (or in the ready-to-use composition or the single anhydrous composition) are those classically used in compositions for the treatment of perspiration. AEROSOLS Compositions A and / or B can still be pressurized and packaged in an aerosol device, including at least one propellant. The propellant used is preferably chosen from dimethyl ether, volatile hydrocarbons such as propane, isopropane, n-butane, isobutane, n-pentane and isopentane and their mixtures, possibly with at least one chlorinated and / or fluorinated hydrocarbon; among the latter we can mention the compounds sold by the company Dupont de Nemours under the names Fréon® and Dymel®, and in particular monofluorotrichloromethane, difluorodichloromethane, tetrafluorodichloroethane and 1,1-difluoroethane sold in particular under the trade name DYMEL 152 A® by the company DUPONT. Carbon dioxide, nitrous oxide, nitrogen or compressed air can also be used as propellants. Preferably, the propellant is chosen from volatile hydrocarbons. Preferably, the propellant is chosen from isopropane, n-butane, isobutane, pentane and isopentane and mixtures thereof. The weight ratio between the liquid phase and the propellant gas varies in a ratio of 5 / 95 to 50 / 50, preferably from 10 / 90 to 40 / 60, and more preferably from 15 / 85 to 30 / 70. According to the invention, the concentration of propellant agent generally varies from 5 to 95% by weight pressurized and more preferably from 50 to 85% by weight relative to the total weight of composition A and / or B pressurized. The dispensing mechanism, which forms part of the aerosol device, generally consists of a dispensing valve controlled by a dispensing head, itself comprising a nozzle through which the mixture of composition A and composition B is vaporized. The container holding each pressurized composition A and B may be opaque or transparent. It may be made of glass, polymeric material, or metal, possibly coated with a protective varnish. Throughout the description, including the claims, the expression "containing a >> shall be understood as synonymous with "containing at least one", unless otherwise specified. The expressions "between ... and ..." and "ranging from ... to ..." should be understood inclusive of limits, unless otherwise specified. In the description and examples, unless otherwise stated, percentages are weight percentages. Therefore, percentages are expressed as a percentage of the total weight of the composition. Temperature is expressed in degrees Celsius unless otherwise stated, and pressure is atmospheric pressure unless otherwise stated. The invention is illustrated in more detail by the non-limiting examples presented below. The following examples serve to illustrate the present invention. Quantities are indicated as percentages by weight relative to the total weight of the composition. Examples 1 to 11: Influence of the choice of modulating agent The following compositions are prepared by mixing the ingredients of composition A on one side, and mixing the ingredients of composition B on the other. Then composition B is introduced into composition A under magnetic stirring. The precipitation reaction time is measured according to the following protocol: the stopwatch is started after mixing compositions A and B in equal volumes, until a precipitate is visually observed: Ingredients Comparative 1 Composition A Composition A1 Composition A2 CaCl2(n) 7.33% 7.33% 7.33% Ascorbic acid (2) - 2% - Citric acid (3) - - 1% Water Qsp100 Qsp100 Qsp100 Ingredients Composition B1 NaHCO3(4) 4.2% Water qsp100 Precipitation reaction time: Between comparative composition A and composition B1; Between compositions A1 and B1; Between compositions A2 and B1: < 0.5s; 32s; 2280s (1) sold under the trade name CALCIUM CHLORIDE DIHYDRATE EMPROVE PH by MERCK (2) sold under the trade name VC ASCORBIC ACID 100 MESH (95%) 50 1584 2 by DSM NUTRITIONAL PRODUCTS (3) sold under the trade name CITRIC ACID MONOHYDRATE by the company CITURGIA BIOCHEMICALS (4) sold under the trade name BICAR FOOD by the company SOLVAY The results thus show that the precipitation reaction between compositions A1 and B1 on the one hand, and A2 and B1 on the other hand (therefore with modulating agent according to the invention), takes place much more slowly than between the comparative compositions A and B1 (without modulating agent). Ingredients Composition A3 Composition A4 Composition A5 Composition A6 Composition A7 CaCl2(1) 7.33% 7.33% 7.33% 7.33% 7.33% acid 2% - - - - Lactic acid (2) Gropionic acid - 1% 2% - - Tartaric acid (4) - - - 1% 2% Water Qsp100 Qsp100 Qsp100 Qsp100 Qsp100 Ingredients Composition B1 NaHCO3 (b) 4.2% Water Qsp100 Precipitation reaction time: Between compositions A3 and B1; Between compositions A4 and B1; Between compositions A5 and B1; Between compositions A6 and B1; Between compositions A7 and B1: 68s; 40s; 43s; 75s; 78s sold under the trade name CALCIUM CHLORIDE DIHYDRATE EMPROVE PH by the company MERCK (2) sold under the trade name PURAC FCC 88 by the company PURAC (3) sold under the trade name PROPIONIC ACID by the company MERCK (4) sold under the trade name NATURAL TARTARIC ACID by the company INDUSTRIA CHIMICA VALENZANA (5) sold under the trade name BICAR FOOD by the company SOLVAY In the same way as before, the results show that the precipitation reaction between compositions A3 and B1, or A4 and B1, or A5 and B1, or A6 and B1 or A7 and B1 (therefore with modulating agent according to the invention), takes place much more slowly than between the comparative compositions A and B (without modulating agent). Ingredients Comparative 2 Composition A Composition A8 Composition A9 Composition A10 CaCl2(n) 1.47% 1.47% 1.47% 1.47% AD1 (2) - 0.056% - - AD2 - - 0.083% AD3 (4) - - - 0.083% Water Qsp100 Qsp100 Qsp100 Qsp100 Ingredients Composition B2 NaHCO3 (b) 0.84% ​​Water qsp100 Precipitation reaction time: Between comparative composition A and composition B2; Between compositions A8 and B2; Between compositions A9 and B2; Between compositions A10 and B2: <30s; 120s; 660s; 480s sold under the trade name CALCIUM CHLORIDE DIHYDRATE EMPROVE PH by the company 5 MERCK (2) sold under the trade name AQUADEW SPA-30 by the company AJINOMOTO (3) sold under the trade name SOKALAN CP42 by BASF 10 (4) sold under the trade name SOKALAN CP44 by the BASF company (5) sold under the trade name BICAR FOOD by the company SOLVAY 15 Here again, the results show that the precipitation reaction between compositions A8 and B2, or A9 and B2, or A10 and B2 (therefore with modulating agent according to the invention), takes place much more slowly than between the comparative 2 compositions A and B2 (without modulating agent). Ingredients Composition A11 MgCl2 (1) 10% Citric acid (2) 1% Sodium citrate (3) 3.2% Water q.s. 100 20 Ingredients Composition B3 Na2HPO4w 7.7% Water Qsp100 Precipitation reaction time between compositions A11 and B3 >7s (1) sold under the trade name MAGNESIUM CHLORIDE HEXA-HYDRATE by the company DR PAUL LOHMANN (2) sold under the trade name CITRIC ACID MONOHYDRATE by the company CITURGIA BIOCHEMICALS (3) sold under the trade name TRISODIUM CITRATE DIHYDRATE FINE F 6000 by the company JUNGBUNZLAUER (4) sold under the trade name DISODIUM PHOSPHATE by the company BK GIULINI CHEMIE Example 12: Composition A in a first emulsion formula The tested composition A12 comprises a base manufactured according to the process described below and containing the ingredients listed in the following table. The application method for this composition is described in example 25: Phase Ingredients Preparation Invention Composition A12 P3 Magnesium Chloride Hexahydrate (1) 10 P3 Citric Acid (2) 1 P3 Sodium Citrate (3) 3.2 P2 Cetearyl Alcohol (4) 2.5 P2 Ceteareth-33 (5) 1.25 P2 Dimethicone (b) 0.5 P1 Pentylene Glycol ( / ) 0.5 P1 Phenoxyethanol (8) 0.5 P1 Water QSP (1) MAGNESIUM CHLORIDE HEXAHYDRATE DR PAUL LOHMANN (2) sold under the trade name CITRIC ACID MONOHYDRATE by the company CITURGIA BIOCHEMICALS (3) sold under the trade name TRISODIUM CITRATE DIHYDRATE FINE F 6000 by the company JUNGBUNZLAUER (4) sold under the trade name LANETTE D by BASF (5) sold under the trade name SIMULSOL CS ECAILLES by the company SEPPIC (6) sold under the trade name BELSIL DM 350 by the company WACKER (7) sold under the trade name 616751 HYDROLITE-5 by the company SYMRISE '8) sold under the trade name SEPICIDE LD by the company SEPPIC Phase P1 was heated to 75°C and phase P2 was melted at 75°C. Phase P2 was slowly introduced into phase P1 while stirring. for 15 minutes. At 40°C, P3 was added and stirred to ensure thorough homogenization. The formula is stable for at least 24 hours. Example 13: Composition A in a second emulsion formula The tested composition A13 comprises a base manufactured according to the process described below and containing the ingredients listed in the following table. The application method for this composition is described in example 25: Phase Ingredients Preparation Invention Composition A13 P1 Water QSP P1 Steareth-1 00 / PEG-1 36 / HDI Copolymer(1) 1 P2 C14-22 Alcohols (and) C12-20 Alkyl Glucoside (2) 3 P2 Dimethicone (3) 7 P3 Magnesium Chloride(4) 10 P3 Citric Acid(t>) 1 P3 Sodium Citrate(b) 3.2 P4 Phenoxyethanol( / ) 0.5 P4 Caprylyl Glycol (8) 0.2 (1) sold under the trade name RHEOLUXE811 by the company ELEMENTIS (2) sold under the trade name MONTANOV L by the company SEPPIC (3) sold under the trade name BELSIL DM 350 by the company WACKER (4) MAGNESIUM CHLORIDE6-HYDRATE DR PAUL LOHMANN (5) sold under the trade name CITRIC ACID MONOHYDRATE by the company CITURGIA BIOCHEMICALS (6) sold under the trade name TRISODIUM CITRATE DIHYDRATE FINE F 6000 by the company JUNGBUNZLAUER (7) sold under the trade name SEPICIDE LD by the company SEPPIC (8) sold under the trade name 199602 HYDROLITE CG by the company SYMRISE Phase P1 is heated to 80°C. Phase P2 is heated to 80°C. Once P1 and P2 are homogeneous and at 80°C, phase P2 is slowly introduced into phase P1 while stirring for 15 minutes. P3 is added and the mixture is stirred to ensure thorough homogenization. At 40°C, phase P4 is added to the mixture while stirring until the preparation has completely cooled (final temperature = 25°C). The formula is stable for at least 24 hours. Example 14: Composition A in a first hydroalcoholic formula The tested composition A14 comprises a base manufactured according to the process described below and containing the ingredients listed in the following table. The application method for this composition is described in example 25: Phase Ingredients Preparation Invention Composition A14 P1 Magnesium Chloride(1) E502105 10 P1 Citric Acid(2) 1 P1 Sodium Citrate^ 3.2 P1 Water 10 P2 PPG-26-Buteth-26 (and) PEG-40 Hydrogenated Castor Oil(4) 3 P1 HydroxyEthylCellulose^ 0.5 P3 Denatured Alcohol (b) 20 P3 Water QSP (1)MAGNESIUM CHLORIDE6-HYDRATE DR PAUL LOHMANN (2) sold under the trade name CITRIC ACID MONOHYDRATE by the company CITURGIA BIOCHEMICALS (3) sold under the trade name TRISODIUM CITRATE DIHYDRATE FINE F 6000 by the company JUNGBUNZLAUER (4) sold under the trade name SOLUBILIZANT LRI by the company SENSIENT (5) sold under the trade name NATROSOL 250 HHR PC by the company ASHLAND (6) sold under the trade name ETHANOL S96 DENATURE BITREX / TERTIO by the company France Alcools Phase P1 was introduced into hot water and stirred for 30 minutes. Phase P2, at 40°C, was slowly introduced into phase P1 while stirring for 15 minutes. At 30°C, phase P3 was added and stirred to ensure thorough homogenization. The formula is stable for at least 24 hours. Example 15: Composition A in a second hydroalcoholic formula The tested composition A15 comprises a base manufactured according to the process described below and containing the ingredients listed in the following table. The application method for this composition is described in example 25: Phase Ingredients Preparation Invention Composition A15 P1 Water QSP P1 Magnesium Chloride(1) 10 P1 Citric Acid(2) 1 P1 Sodium Citrate^ 3.2 P2 Hydroxyethylcellulose 0.55 P4 Alcohol Denat(0) 16.54 P3 PEG-60 Hydrogenated Castor Oil(6) 1.2 (1) MAGNESIUM CHLORIDE6-HYDRATE DR PAUL LOHMANN (2) sold under the trade name CITRIC ACID MONOHYDRATE by the company CITURGIA BIOCHEMICALS (3) sold under the trade name TRISODIUM CITRATE DIHYDRATE FINE F 6000 by the company JUNGBUNZLAUER (4) sold under the trade name NATROSOL 250 HHR PC by the company ASHLAND '5) sold under the trade name ETHANOL S96 DENATURE BITREX / TERTIO by the company FRANCE ALCOOLS (6) sold under the trade name EUMULGINCO60 by BASF Phase P1 is heated to 50°C. Phase P2 is added while stirring until a homogeneous phase is obtained. Phase P3 is melted at 40°C and added to the P1+P2 mixture while stirring at 40°C. The mixture is allowed to cool to room temperature while stirring, and then phase P4 is added. The formula is stable for at least 24 hours. Examples 16-17: Composition A and composition B separately in a reverse emulsion formula The tested compositions A16 and B4 comprise a base manufactured according to the process described below and containing the ingredients listed in the following table. The application method for these compositions is described in Example 25: Phase Ingredients Preparation Invention Composition A16 P1 Water q.s.p. P1 Magnesium Chloride (1) 10 P1 Citric Acid (2) 1 P1 Sodium Citrate (3) 3.2 P1 Phenoxyethanol (t>) 0.7 P2 PEG-30 Dipolyhydroxystearate (6) 0.8 P2 Dicapryl Carbonate ( / ) 6 P2 Isopropyl Palmitate (b) 10 P2 PolyC10-30 Alkyl Acrylate (9) 0.1 P2 Lauryl PEG / PPG-18 / 1 8 Methicone (and) Dodecene (and) Poloxamer 407 (10) 0.4 Phase Ingredients Preparation Invention Composition B4 P1 Water QSP P1 Dipotassium Phosphate (4) 10 P1 Phenoxyethanol (t>) 0.7 P2 PEG-30 Dipolyhydroxystearate 0.8 P2 Dicaprilylcarbonate ( / ) 6 P2 Isopropyl Palmitate^ 10 P2 PolyC10-30 alkylacrylate (9) 0.1 P2 Lauryl PEG / PPG-18 / 1 8 methicone (and) Dodecene (and) Poloxamer 407(10) 0.4 (1) MAGNESIUM CHL0RIDE6-HYDRATE DR PAUL LOHMANN (2) sold under the trade name CITRIC ACID 5 MONOHYDRATE by CITURGIA BIOCHEMICALS (3) sold under the trade name TRISODIUM CITRATE DIHYDRATE FINE F 6000 by the company JUNGBUNZLAUER ( 'sold under the trade name DI POTASSIUM HYDROGEN PHOSPHATE ANHYDROUS EMPROVE EXP PH EU R, BP,E340 by the company MERCK (5) sold under the trade name SEPICIDE LD by the company SEPPIC (6) sold under the trade name CITHROL DPHS-SO-(MV) by the company CRODA (7) sold under the trade name CETIOL CC by BASF (8) sold under the trade name ISOPROPYL PALMITATE / MB by BASF (9) sold under the trade name INTELIMERIPA13-1 NG POLYMER by the company EVONIK (AIR PRODUCTS) (10) sold under the trade name DOW CORNING 5200 FORMULATION AID by DOW CORNING For each composition A16 and B4, the protocol is as follows: Phase P1 is homogenized at room temperature. Phase B is heated to 60°C. Once P1 and P2 are homogenized, phase P1 is slowly introduced into phase P2 while stirring for 10 minutes. Each formula is stable for at least 24 hours. Example 18: Anhydrous aerosol formula The tested formula includes a base manufactured according to the process described below and containing the ingredients listed in the following table: Phase Ingredients Preparation Invention Example 18 P1 Isopropyl palmitate(1) 26.13 P1 Isododecane(2) 15 P1 Coconut oil (3) 7 P2 Disteardimonium hectorite (4) 2.6 P3 Propylene carbonate(t>) 0.87 P4 Magnesium chloride(6) 20 P4 Citric acid( / ) 2 P4 Sodium citrate(8) 6.4 P4 Dipotassium phosphate(9) 20 (1) sold under the trade name Isopropyl Palmitate by the company Cognis (BASF) (2) sold under the trade name Isododecane by the company Ineos (3) sold under the trade name REFINED COPRAH OIL GV 24 / 26 by the company Sio (ADM) (4) sold under the trade name Bentone 38VCG by the company Elementis (5) sold under the trade name Jeffsol propylene carbonate by the Huntsman company (6) MAGNESIUM CHLORIDE6-HYDRATE DR PAUL LOHMANN (7) sold under the trade name CITRIC ACID ANHYDROUS by the company CARGILL '8) sold under the trade name TRISODIUM DIHYDRATE FINE F 6000 by JUNGBUNZLAUER (9) sold under the trade name DI POTASSIUM HYDROGEN PHOSPHATE ANHYDROUS EMPROVE EXP PH EU R, BP, E340 by MERCK Phase P1 was mixed with stirring. Phase P2 was slowly introduced into phase P1 and allowed to expand for five minutes. Phase P3 was then added. The mixture was stirred vigorously until well homogenized. Phase P4 was then gradually added until homogenized. The formula is stable for at least 24 hours. Examples 19 to 24: Composition A and composition B separately in aqueous gel formula The tested compositions A19, A20 and B5, B6, B7, B8 comprise a base manufactured according to the process described below and containing the ingredients listed in the following table. The application method for these compositions is described in Example 25: Phase Ingredients Preparation Invention Composition B5 P1 Water q.s. P2 Hydroxyethyl Cellulose *2' 0.75 P3 Dipotassium Phosphate*6' 7.7 P4 Phenoxyethanol*7' 0.5 Phase Ingredients Preparation Invention Composition B6 P1 Water q.s. P2 Hydroxyethyl Cellulose *2' 0.75 P3 Disodium Phosphate*8' 7.7 P4 Phenoxyethanol*7' 0.5 Phase Ingredients Preparation Invention Composition B7 P1 Water QS P2 Sclerotium Gum*1' 1 P3 Dipotassium Phosphate*6' 7.7 P4 Phenoxyethanol*7' 0.5 Phase Ingredients Preparation Invention Composition B8 P1 Water QSP P2 Sclerotium Gum*1' 1 P3 Disodium Phosphate*8' 7.7 P4 Phenoxyethanol*7' 0.5 Phase Ingredients Preparation Invention Composition A19 P1 Water QSP P2 Hydroxyethyl Cellulose *2' 0.75 P3 Magnesium Chloride (3) 10 P3 Citric Acid*4' 1 P3 Sodium Citrate*5' 3.2 P4 Phenoxyethanol*7' 0.5 Phase Ingredients Preparation Invention Composition A20 P1 Water q.s. P2 Sclerotium Gum(1) 1 P3 Magnesium Chloride (3) 10 P3 Citric Acid(4) 1 P3 Sodium Citrate(5) 3.2 P4 Phenoxyethanol(7) 0.5 (1) sold under the trade name AMIGEL GRANULE by the company ALBAN MULLER (2) sold under the trade name NATROSOL 250 HHR PC by the company ASHLAND Î3) MAGNESIUM CHLORIDE6-HYDRATE DR PAUL LOHMANN (4) sold under the trade name CITRIC ACID MONOHYDRATE by the company CITURGIA BIOCHEMICALS (5) sold under the trade name TRISODIUM CITRATE DIHYDRATE FINE F 6000 by the company JUNGBUNZLAUER (6) sold under the trade name DI POTASSIUM HYDROGEN PHOSPHATE ANHYDROUS EMPROVE EXP PH ER, BP, E340 by the company MERCK (7) sold under the trade name SEPICIDE LD by the company SEPPIC (8) sold under the trade name DISODIUM PHOSPHATE by the company BK GIULINI CHEMIE For each composition A19, A20, and B5, B6, B7, B8, the protocol is as follows: Phase P2 is introduced into phase P1 while stirring. Once the mixture is homogeneous, phase P3 is added while stirring. Then phase P4 is introduced while stirring. The formulas are stable for at least 24 hours. Example 25: Methods for applying compositions A and B according to the invention 1) Aqueous formulas: Each aqueous composition A1 to A16, A19 and A20 of the examples above can be applied with one of the aqueous compositions B1 to B8. To achieve this, the application process may include: - the mixing just before use of at least one composition A chosen from A1 to A16, A19 and A20, with a composition B chosen from B1 to B6, followed by the application of the resulting mixture to the surface of the skin; - the application to the skin surface, simultaneously or sequentially, of at least one composition A chosen from A1 to A16, A19 and A20, and at least one composition B chosen from B1 to B8. Composition A, chosen from A1 to A16, A19 and A20, and composition B, chosen from B1 to B8, may be present in two separate media, or in the same medium. 2) Anhydrous formula: Typically, the anhydrous composition of example 18 already contains the mixture of cation Xn+, anion Ym' and modulating agent, and is applied directly to the skin. Example 26: Clinical efficacy of antiperspirants Method: A gravimetric test was performed with compositions A11 and B3 from Example 11 to measure their antiperspirant efficacy, compared to a control formula containing water. In short, after a three-week washout period, thirty-four subjects were treated twice daily for four days in the axillary area with 400 µl of each composition applied alternately (composition A11 followed by composition B3), with a light massage between applications. Twenty-four hours after the last application, the volunteers were subjected to a sauna at 38°C and 35% RH (humidity) for forty minutes, during which their axillary sweat was collected using pre-weighed cotton pads, which were weighed after collection. Results : We observe an 8.9% reduction in the amount of sweat for the group treated according to the invention compared to the control group with a significance p < 0.017.

Claims

DEMANDS 1. A cosmetic process for treating human perspiration and optionally body odor resulting from perspiration, comprising the use of at least one cation Xn+ of valence n, at least one anion Ym' of valence m and at least one modulating agent, in which said cation Xn+ is multivalent inorganic and selected from: (i) alkaline earth cations, and (ii) transition metal cations, and said anion Ym' is chosen from carbonate (COs2'), hydrogen carbonate (HCO3'), phosphate (PO43), polyphosphates such as diphosphate P2O74”, triphosphate P3O105 > phosphonate (PO33), hydrogen phosphate (HPO42), sulfate (SO42), sulfonate (SO32), hydrogen sulfate (HSO4), hydrogen sulfonate (HSO3) and silicate (S1O32).

2. A process according to claim 1, characterized in that the cation Xn+ of valence n, the anion Ym' of valence m and the modulating agent are formulated in an anhydrous medium within the same composition.

3. A method according to claim 1, characterized in that: - the cation Xn+ with valence n is present in a composition A; - the anion Y"1' with valence m is present in a composition B, compositions A and B being different; and - the modulating agent is present in composition A and / or in composition B.

4. A method according to claim 1, characterized in that: - the cation Xn+ with valence n is present in a composition A; - the anion Y"1' with valence m is present in a composition B, compositions A and B being different; and - the modulating agent is generated during the mixing of compositions A and B.

5. A method according to any one of claims 1, 3 or 4, comprising: (i) either the mixing just before use of at least one composition A and at least one composition B, said compositions A and B being packaged separately, followed by the application of the resulting mixture to the surface of the skin; (ii) either the application to the skin surface simultaneously or sequentially of at least one composition A and at least one composition B packaged separately; (iii) either the application to the skin surface of a composition comprising in the same carrier at least one composition A and at least one composition B; said composition A comprising, in a cosmetically acceptable medium, at least one salt of the cation Xn+ of valence n, the counter-ion being distinct from the anion Yæ' of valence m; and said composition B comprising, in a cosmetically acceptable medium, at least one salt of anion Ym' of valence m, the counter-ion being distinct from the cation Xn+ of valence n 6. A method according to any one of claims 1 to 5, wherein the alkaline earth Xn+ cation is selected from Magnesium and Calcium.

7. A method according to any one of claims 1 to 6, wherein the transition metal Xn+ cation is selected from Zinc, Manganese, Titanium and Iron.

8. A process according to any one of claims 1 to 7, wherein the cation Xn+ is in the form of a water-soluble salt, preferably selected from halides, sulfates and carboxylates.

9. A method according to any one of claims 5 to 8, wherein the cation salt Xn+ is selected from calcium chloride, magnesium chloride, calcium pidolate, calcium aspartate, calcium gluconate, calcium glutamate, calcium heptagluconate, calcium propionate, calcium 2-ketogluconate, calcium lactate, calcium ascorbate, calcium citrate, magnesium acetate, magnesium pidolate, magnesium gluconate, magnesium glutamate, magnesium heptagluconate, magnesium 2-ketogluconate, magnesium lactate, magnesium ascorbate, magnesium citrate, magnesium aspartate, and magnesium gluconate. Manganese and Magnesium sulfate.

10. A process according to claim 9, wherein the cation salt Xn+ is selected from Calcium chloride, Magnesium chloride, Calcium acetate and Magnesium lactate.

11. A method according to any one of claims 1 to 10, wherein the anion Ym' is selected from hydrogen phosphate and hydrogen carbonate.

12. A method according to any one of claims 1 to 11, wherein the anion Yæ' is in the form of a salt preferably selected from: - alkali metal salts such as potassium or sodium, and - ammonium salts, such as alkanolamine salts, comprising one to three hydroxyalkyl radicals, identical or not, in Ci-C4.

13. A method according to any one of claims 1 to 12, wherein the anion Ymest is in the form of an alkali metal salt, in particular a sodium or potassium salt.

14. A method according to any one of claims 1 to 13, wherein the anion Ym is in the form of a salt selected from Na2CO3, K2CO3, NaHCO3, KHCO3, Na3PO3, Na2HPO4, NaH2PO4, Na2H2P2O7, Na4P2O7, K2HPO4, KH2PO4, K2H2P2O7, K4P2O7, Na2SO4, MgSO4, K2SO4 and preferably NaHCO3 and K2HPO4.

15. A method according to any one of claims 1 to 14, wherein the molar ratio between the cation Xn+ and the anion Ym' varies from 10:1 to 1:10 and more preferably from 4:1 to 1:

4.

16. A method according to any one of claims 3 to 15, wherein the total concentration of cation Xn+ and anion Ym' varies from 1 to 70% by weight and more preferably from 2 to 50% by weight relative to the total weight of compositions A and B.

17. A method according to any one of claims 1 to 15, wherein the modulating agent is chosen from among the complexing agents of the Xn+ cation.

18. A method according to any one of claims 1 to 17, wherein the modulating agent is selected from: - mono- or polycarboxylic acids, possibly hydroxylated, in free or salt form, such as propionic acid, citric acid, tartaric acid, lactic acid, malic acid, succinic acid, glutaric acid, itaconic acid, - Amino carboxylic acids in free or salted form such as aspartic acid, glutamic acid, serine, alanine, dehydroalanine and their oligomers, iminosuccinic acid and its derivatives, ethylenediaminetetraacetic acid, - monosaccharides, oligosaccharides, polysaccharides and their derivatives, preferably selected from glucose, galactose, mannose, xylose, lyxose, fucose, arabinose, rhamnose, ribose, deoxyribose, quinovose, fructose, sorbose, talose, threose, erythrose, trehalose, lactose, maltose, cellobiose, glucuronic acid, lactobionic acid, alginates, chitosans and pectins, - ascorbic acid, - phytic acid, - polymers or copolymers of carboxylic acids in free or salted form, - polymers or copolymers of amino carboxylic acids in free or salted form such as polyaspartic acid; polyglutamic acid, - polymers and copolymers of maleic or itaconic acid, and - Carboxymethylinulin polymers and copolymers.

19. A method according to claim 18, wherein the modulating agent is selected from amino carboxylic acids in free or salified form, mono- or polycarboxylic acids optionally hydroxylated in free or salified form, ascorbic acid, polymers or copolymers of amino carboxylic acids in free or salified form such as polyaspartic acid, or polymers or copolymers of carboxylic acids in free or salified form.

20. A process according to claim 18, wherein the modulating agent is selected from citric acid, ascorbic acid, lactic acid, propionic acid, tartaric acid or polyaspartic acid, in free or salted form, or a polymer or copolymer of carboxylic acids, optionally amines.

21. A method according to any one of claims 3 to 20, wherein composition A comprising the cation Xn+ and composition B comprising the flag Ym' are conditioned separately and applied to the skin surface simultaneously or sequentially with a time interval of 1 second to 24 hours, more preferably 10 seconds to 24 hours and even more preferably 1 minute to 1 hour.

22. Cosmetic composition, in particular for the treatment of human perspiration and possibly body odors resulting from perspiration, ready to the use, which comprises, in a cosmetically acceptable medium, at least one cation salt Xn+ of valence n, at least one anion salt Ym' of valence m and at least one modulating agent, said composition comprising less than 5% by weight relative to the total weight of aluminum salt composition, and said cation Xn+ 5 being a multivalent inorganic compound chosen from: (i) alkaline earth cations, and (ii) transition metal cations.